Accuray (ARAY) 10-K 17 Aug 22 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2022	Aug. 09, 2022	Dec. 31, 2021
Cover [Abstract]
Entity Registrant Name	ACCURAY INCORPORATED
Entity Central Index Key	0001138723
Document Type	10-K
Document Period End Date	Jun. 30, 2022
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Trading Symbol	ARAY
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 365,403,546
Entity Common Stock, Shares Outstanding		93,499,500
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-33301
Entity Tax Identification Number	20-8370041
Entity Address, Address Line One	1310 Chesapeake Terrace
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94089
City Area Code	408
Local Phone Number	716‑4600
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	true
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the Proxy Statement for the Registrant’s 2022 Annual Meeting of stockholders (the “2022 Proxy Statement”) are incorporated by reference in Part III of this Form 10‑K.
Auditor Name	GRANT THORNTON LLP
Auditor Location	San Jose, California
Auditor Firm ID	248

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2022	Jun. 30, 2021
Current assets:
Cash and cash equivalents		$ 88,737	$ 116,369
Restricted cash		204	560
Accounts receivable, net of allowance for credit losses of $1,000 and $1,048 as of June 30, 2022 and June 30, 2021, respectively	[1]	94,442	85,360
Inventories		142,254	125,929
Prepaid expenses and other current assets	[2]	23,794	21,547
Deferred cost of revenue		1,459	3,008
Total current assets		350,890	352,773
Property and equipment, net		12,685	12,332
Investment in joint venture		13,879	15,935
Operating lease right-of-use assets, net		16,798	22,522
Goodwill		57,840	57,960
Intangible assets, net		250	435
Restricted cash		1,213	1,272
Other assets		19,294	16,869
Total assets		472,849	480,098
Current liabilities:
Accounts payable		31,337	19,467
Accrued compensation		29,441	26,865
Operating lease liabilities, current		8,567	8,169
Other accrued liabilities		30,285	27,471
Customer advances		25,290	24,937
Deferred revenue		75,375	81,660
Short-term debt		8,563	3,790
Total current liabilities		208,858	192,359
Long-term liabilities:
Operating lease liabilities, non-current		10,453	17,441
Long-term other liabilities		3,748	7,766
Deferred revenue		24,694	23,685
Long-term debt		171,907	170,007
Total liabilities		419,660	411,258
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding		0	0
Common stock, $0.001 par value; authorized: 200,000,000 shares as of June 30, 2022 and June 30, 2021, respectively; issued and outstanding: 93,499,500 and 90,821,661 shares at June 30, 2022 and June 30, 2021, respectively		94	91
Additional paid-in-capital		543,211	554,680
Accumulated other comprehensive income		2,406	2,093
Accumulated deficit		(492,522)	(488,024)
Total stockholders' equity		53,189	68,840
Total liabilities and stockholders’ equity		$ 472,849	$ 480,098
[1] Included accounts receivable from the China joint venture of $ 24,828 and $ 8,822 at June 30, 2022 and June 30, 2021, respectively. See Note 13 Included other receivable from the China joint venture o f $ 861 a t June 30, 2022 and $ 187 at June 30, 2021, respectively.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Accounts receivable, allowance for credit losses (in dollars)	$ 1,000	$ 1,048
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, issued shares	93,499,500	90,821,661
Common stock, outstanding shares	93,499,500	90,821,661
Accounts receivable from joint venture	$ 24,828	$ 8,822
Prepaid Expenses and Other Current Assets
Accounts receivable from joint venture	$ 861	$ 187

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Net revenue:
Total net revenue		$ 429,909	$ 396,289	$ 382,928
Cost of revenue:
Total cost of revenue	[1]	269,954	236,782	233,207
Gross profit		159,955	159,507	149,721
Operating expenses:
Research and development	[2]	57,752	52,729	49,784
Selling and marketing		49,664	42,820	47,254
General and administrative		44,391	41,723	40,144
Total operating expenses		151,807	137,272	137,182
Income from operations		8,148	22,235	12,539
Income (loss) on equity method investment		241	872	(149)
Other expense, net		(10,391)	(27,666)	(6,700)
Income (loss) before provision for income taxes		(2,002)	(4,559)	5,690
Provision for income taxes		3,345	1,752	1,863
Net income (loss)		$ (5,347)	$ (6,311)	$ 3,827
Net income (loss) per share - basic		$ (0.06)	$ (0.07)	$ 0.04
Net income (loss) per share - diluted		$ (0.06)	$ (0.07)	$ 0.04
Weighted average common shares used in computing net income (loss) per share:
Basic		92,095	92,031	89,874
Diluted		92,095	92,031	90,623
Net income		$ (5,347)	$ (6,311)	$ 3,827
Foreign currency translation adjustment		(3,998)	1,705	(238)
Change in defined benefit pension obligation		4,311	872	(236)
Comprehensive income (loss)		(5,034)	(3,734)	3,353
Products
Net revenue:
Total net revenue	[3]	214,715	176,647	167,302
Cost of revenue:
Total cost of revenue		127,287	102,100	95,882
Services
Net revenue:
Total net revenue	[4]	215,194	219,642	215,626
Cost of revenue:
Total cost of revenue		$ 142,667	$ 134,682	$ 137,325
[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $ 35,237 for the yea r ended June 30, 2022, $ 13,310 for the year ended June 30, 2021 and $ 13,174 for the year ended June 30, 2020, respectively. See Note 13. Includes chargeback to the China joint venture, an equity method investment related to research and development project of $ 2,336 and $ 430 for the year ending June 30, 2022 and June 30, 2021, respectively Includes sales to the China joint venture, an equity method investment of $ 45,545 for the year ended June 30, 2022, $ 12,033 for the year ended June 30, 2021 and $ 11,202 for the year ended June 30, 2020, respectively. See Note 13. Includes sales to the China joint venture, an equity method investment of $ 10,332 for the year ended June 30, 2022, $ 12,360 for the year ended June 30, 2021 and $ 7,851 for the year ended June 30, 2020, respectively. See Note 13.

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Total net revenue		$ 429,909	$ 396,289	$ 382,928
Total cost of revenue	[1]	269,954	236,782	233,207
Research and development	[2]	57,752	52,729	49,784
Products
Total net revenue	[3]	214,715	176,647	167,302
Total cost of revenue		127,287	102,100	95,882
Services
Total net revenue	[4]	215,194	219,642	215,626
Total cost of revenue		142,667	134,682	137,325
Revenue from Joint Venture
Total cost of revenue		35,237	13,310	13,174
Research and development		2,336	430
Revenue from Joint Venture | Products
Total net revenue		45,545	12,033	11,202
Revenue from Joint Venture | Services
Total net revenue		$ 10,332	$ 12,360	$ 7,851
[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $ 35,237 for the yea r ended June 30, 2022, $ 13,310 for the year ended June 30, 2021 and $ 13,174 for the year ended June 30, 2020, respectively. See Note 13. Includes chargeback to the China joint venture, an equity method investment related to research and development project of $ 2,336 and $ 430 for the year ending June 30, 2022 and June 30, 2021, respectively Includes sales to the China joint venture, an equity method investment of $ 45,545 for the year ended June 30, 2022, $ 12,033 for the year ended June 30, 2021 and $ 11,202 for the year ended June 30, 2020, respectively. See Note 13. Includes sales to the China joint venture, an equity method investment of $ 10,332 for the year ended June 30, 2022, $ 12,360 for the year ended June 30, 2021 and $ 7,851 for the year ended June 30, 2020, respectively. See Note 13.

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative adjustment due to adoption of ASU No 2020-06	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative adjustment due to adoption of ASU No 2020-06	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated Deficit Cumulative adjustment due to adoption of ASU No 2020-06
Balance at Jun. 30, 2019	$ 49,871		$ 89	$ 535,332		$ (10)	$ (485,540)
Balance (in shares) at Jun. 30, 2019			88,521,511
Issuance of restricted stock	(206)		$ 1	(207)
Issuance of restricted stock (in shares)			1,579,037
Issuance of common stock under employee stock purchase plan	2,451		$ 1	2,450
Issuance of common stock under employee stock purchase plan (in shares)			1,136,096
Share-based compensation	8,166			8,166
Tax withholding upon vesting of restricted stock units (in shares)			(58,536)
Net income	3,827						3,827
Cumulative translation adjustment	(238)					(238)
Change in defined benefit pension obligation	(236)					(236)
Balance at Jun. 30, 2020	63,635		$ 91	545,741		(484)	(481,713)
Balance (in shares) at Jun. 30, 2020			91,178,108
Exercise of options, net	855			855
Exercise of options, net (in shares)			209,008
Issuance of restricted stock	2		$ 2
Issuance of restricted stock (in shares)			1,452,618
Issuance of common stock under employee stock purchase plan	2,174		$ 1	2,173
Issuance of common stock under employee stock purchase plan (in shares)			1,168,220
Repurchase of common stock	(14,081)		$ (3)	(14,078)
Repurchase of common stock (in shares)			(3,108,369)
Share-based compensation	9,385			9,385
Tax withholding upon vesting of restricted stock units (in shares)			(77,924)
Extinguishment of allocated cost related to convertible note exchange	(14,562)			(14,562)
Bifurcation of conversion option upon issuance of convertible notes	25,166			25,166
Net income	(6,311)						(6,311)
Cumulative translation adjustment	1,705					1,705
Change in defined benefit pension obligation	872					872
Balance at Jun. 30, 2021	$ 68,840	$ (24,784)	$ 91	554,680	$ (25,633)	2,093	(488,024)	$ 849
Balance (in shares) at Jun. 30, 2021	90,821,661		90,821,661
Exercise of options, net	$ 1,224		$ 1	1,223
Exercise of options, net (in shares)			331,401
Issuance of restricted stock	(257)		$ 1	(258)
Issuance of restricted stock (in shares)			1,292,744
Issuance of common stock under employee stock purchase plan	2,665		$ 1	2,664
Issuance of common stock under employee stock purchase plan (in shares)			1,053,694
Share-based compensation	10,535			10,535
Net income	(5,347)						(5,347)
Cumulative translation adjustment	(3,998)					(3,998)
Change in defined benefit pension obligation	4,311					4,311
Balance at Jun. 30, 2022	$ 53,189		$ 94	$ 543,211		$ 2,406	$ (492,522)
Balance (in shares) at Jun. 30, 2022	93,499,500		93,499,500

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net income (loss)	$ (5,347)	$ (6,311)	$ 3,827
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	5,513	6,389	7,541
Share-based compensation	10,600	9,332	8,152
Amortization of debt issuance costs	817	1,356	1,348
Accretion of interest on debt	0	4,887	4,168
Provision for credit losses	266	133	1,797
Non-cash revenue transactions related to joint venture	0	(1,365)	0
Provision for write-down of inventories	3,478	6,914	4,184
Loss on disposal of property and equipment	28	106	9
(Income) loss on equity method investment	(241)	(872)	149
Release (deferral) of equity method investment intra-entity profit on sales	3,300	310	1,847
Loss on extinguishment of debt	0	9,948	0
Gain on contribution to joint venture	0	0	(12,964)
Provision (benefit) for deferred income taxes	1,785	(114)	353
Changes in assets and liabilities:
Accounts receivable, short and long-term	(12,519)	5,235	19,030
Inventories	(22,861)	1,688	(23,178)
Prepaid expenses and other assets	(6,042)	(951)	4,403
Deferred cost of revenue, short and long-term	1,549	(296)	(2,441)
Accounts payable	11,676	(3,978)	(6,770)
Operating lease liabilities, net	(880)	(663)	(235)
Accrued liabilities	6,685	8,089	(16,595)
Customer advances	1,238	2,237	2,159
Deferred revenues, short and long-term	(1,445)	(3,562)	1,747
Net cash provided by (used in) operating activities	(2,400)	38,512	(1,469)
Cash flows from investing activities
Purchases of property and equipment, net	(4,717)	(2,320)	(3,558)
Purchase of intangible assets	0	0	(170)
Additional investments in joint venture	0	(79)	0
Net cash (used in) investing activities	(4,717)	(2,399)	(3,728)
Cash flows from financing activities
Proceeds from employee stock plans	2,341	2,175	2,450
Proceeds from exercise of options	1,548	855	0
Taxes paid related to net share settlement of equity awards	(258)	(343)	(207)
Convertible senior notes exchange and issued, net of issuance costs	0	(142)	0
Paydown and repayment of prior term loan and prior revolving credit facility	0	(115,924)	0
Proceeds from New Debt, net of costs	0	103,654	24,716
Repayments under the New Term loan	(4,000)	0	0
Borrowings (repayments) under the New Revolving Credit Facility, net	(15,000)	(5,000)	(263)
Stock repurchase	0	(14,080)	0
Net cash provided by (used in) financing activities	(15,369)	(28,805)	26,696
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(5,561)	982	234
Net increase (decrease) in cash, cash equivalents and restricted cash	(28,047)	8,290	21,733
Cash, cash equivalents and restricted cash at beginning of period	118,201	109,911	88,178
Cash, cash equivalents and restricted cash at end of period	90,154	118,201	109,911
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	1,398	1,873	2,806
Cash paid for interest	7,462	11,892	12,332
Supplemental non-cash disclosure:
Non-cash effect of pension settlement accounting	0	0	178
Prior convertible note exchanged	0	(82,135)	0
New convertible note exchanged	0	97,148	0
Unpaid purchase of property and equipment at end of year	813	555	226
Transfers from inventory to property and equipment	0	564	2,594
Equity method investment, in exchange for non-cash contributions of assets to China Joint Venture (including gain of $12,964)	$ 0	$ 0	$ 15,925

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Jun. 30, 2020 USD ($)
Gain on contribution to equity method investment	$ (149)
Joint Venture [Member]
Gain on contribution to equity method investment	$ 12,964

The Company and its Significant

The Company and its Significant Accounting Policies	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and its Significant Accounting Policies	Note 1. The Company and its Significant Accounting Policies The Company Accuray Incorporated (together with its subsidiaries, the “Company” or “Accuray”) designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company is incorporated in Delaware and has its principal place of business in Sunnyvale, California. The Company has primary offices in the United States, Switzerland, China, Hong Kong and Japan and conducts its business worldwide. Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Risks and Uncertainties The Company is subject to risks and uncertainties as a result of a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, which causes coronavirus disease 2019 (“COVID-19”) and has resulted in a worldwide pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the effects of and response to the pandemic are rapidly evolving and new information is regularly coming to light, particularly as new COVID-19 variants emerge. The Company's customers are diverting resources to treat COVID-19 patients and deferring non-urgent and elective procedures. Some customers, which include hospitals, major academic medical centers, and other related entities, have incurred significant losses during the COVID-19 pandemic due to reduced patient volume. These impacts on the Company's customers may adversely affect their ability to meet their financial and other contractual obligations, including to the Company. Furthermore, global economic uncertainty, including labor shortages and disruptions in the global supply chain, related to the COVID-19 pandemic may result in an incremental adverse impact on revenue, net income (loss) and cash flow and may require significant additional expenditures or cost-cutting to mitigate such impacts. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. The Company’s financial results have also been affected by the COVID-19 pandemic in various ways. The COVID-19 pandemic is adversely impacting the pace at which the Company’s backlog converts to revenue. This is primarily the result of pandemic-related delays in the timing of deliveries and installations, which has adversely affected our revenue. The Company has experienced such delays in deliveries and installations since the third quarter of fiscal year 2020 and expects that such delays in will continue, which could have a negative impact on revenue. The Company has experienced disruptions in its sales cycle as well as delays in customer payments and service agreements. The Company has also received requests from a few customers to extend payment terms or temporarily suspend service and corresponding payment obligations. While the Company has only received a small number of requests thus far, there can be no guarantee that more customers will not ask for the same in the future. In addition, as the COVID-19 pandemic continues to impact the global supply chain, disruptions in parts of our supply chain have resulted in delays in the receipt of certain components for our products as well as increased pricing pressure for such parts. These ongoing supply chain challenges and heightened logistics costs have adversely affected the Company's gross margins and net income (loss), and the Company’s current expectations are that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistic expenses through at least the remainder of the calendar year of 2022, if not longer. Furthermore, certain parts required for the manufacture and servicing of the Company's products, such as electronic components, are scarce and becoming increasingly difficult to source even at increased prices. If such parts become unavailable to the Company, it would not be able to manufacture or service our products, which would adversely impact revenue, gross margins, and net income (loss). As a result, the Company is carefully monitoring the pandemic and the potential length and depth of the resulting economic impact on our financial condition and results of operations. There remain uncertainties around the spread, severity and potential resurgence of COVID-19, the impact of new COVID-19 variants, vaccination deployment efforts, and how long the pandemic and associated health measures will last, the related financial impact cannot be reasonably estimated at this time, although the impacts are expected to continue and may significantly affect the Company’s business. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. However, the Company is unable to predict with certainty the impact of the COVID-19 pandemic, including its effect on global supply chain and logistics, will have on its ability to maintain compliance with the debt covenants contained in the credit agreement related to its Credit Facilities (as such terms are defined in Note 10 below), including financial covenants regarding the consolidated fixed charge coverage ratio and consolidated senior net leverage ratio. The Company was in compliance with such covenants at June 30, 2022. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be accelerated and become immediately payable. This may require the Company to obtain waivers or amendments to the credit agreement in order to maintain compliance and there can be no certainty that any such waiver or amendment will be available, or what the cost of such waiver or amendment, if obtained, would be. If the Company is unable to obtain necessary waivers or amendment and the debt under such credit facility is accelerated, the Company would be required to obtain replacement financing at prevailing market rates, which may not be favorable to the Company. There is no guarantee that the Company would be able to satisfy its obligations if any of its indebtedness is accelerated . Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic. Key estimates and assumptions made by the Company relate to revenue recognition and the assessment of stand-alone selling price (“SSP”), assessment of recoverability of goodwill, valuation of the Company's equity method investment in the JV, valuation of inventories, annual performance related bonuses, allowance for credit losses and loss contingencies. Actual results could differ materially from those estimates. Foreign Currency The Company’s international subsidiaries use their local currencies as their functional currencies. For those subsidiaries, assets and liabilities are translated at exchange rates in effect at the balance sheet date and income and expense accounts at the average exchange rate. Resulting translation adjustments are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive loss as a separate component of stockholders’ equity. Net foreign currency exchange transaction gains or losses are included as a component of other expense, net, in the Company’s consolidated statements of operations and comprehensive income (loss). Fair Value Measurements The carrying values of the Company’s financial instruments including cash equivalents, restricted cash, accounts receivable and accounts payable are approximately equal to their respective fair values due to the relatively short‑term nature of these instruments. Also refer to Note 8, Fair Value Measurements, for further details. Cash and Cash Equivalents The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States and internationally. Concentration of Credit Risk and Other Risks and Uncertainties The Company’s cash and cash equivalents are mainly deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances. The Company ha d one customer t hat represented 10 % or more of total net revenue for the year ended June 30, 2022 and one and no customer that represented 10 % or more of total net revenue for the years ended June 30, 2021 and 2020, respectively. The Company had two customers as of June 30, 2022 and two customers as of June 30, 2021, respectively that each accounted for more than 10 % of accounts receivable, net. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for credit losses once collection efforts are unsuccessful. Historically, such losses have been within management’s expectations. Single‑source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required. Restricted Cash Restricted cash primarily consists of cash that is temporarily held in bank accounts which are under the control of the lender to the New Credit Facility, certificates of deposit held as guarantees in connection with customer contracts and corporate leases as well as funds held as guarantees for Value‑Added Tax (VAT) obligations in a foreign jurisdiction. Inventories Inventories are stated at the lower of cost (on a first‑in, first‑out basis) or net realizable value. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management. Revenue Recognition The Company’s revenue consists of product revenue resulting from the sale of systems, system upgrades and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer, net of any discounts and taxes collected from customers that are remitted to government authorities. The Company’s revenue is primarily derived from sales of CyberKnife and TomoTherapy platforms and services, which include post-contract customer support (“PCS”), installation services, training and other professional services. The majority of the Company's revenue arrangements consist of multiple performance obligations, which can include system, upgrades, installation, training, services, construction, and consumables. For bundled arrangements, the Company accounts for individual products and services separately if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s products are generally sold without a right of return, and the Company’s contracts generally provide a fixed transaction price. The Company may offer incentives in the form of discounts, including volume system discounts, which are included in the contract and used to calculate the final fixed price of the arrangement. These discounts may pertain to all performance obligations in a specific contract or may be allocated to a specific performance obligation. The Company reviews payment terms extending beyond one year. If it is determined that a material financing component exists, we recognized as interest income over time. The Company applies the practical expedient to not adjust for a significant financing component if the gap between payment and delivery was expected, at the contract inception, to be less than one year. The Company offers customers the opportunity to trade in their older systems for a discount off the purchase of a new system. The Company generally does not provide specific trade-in prices or upgrade rights at the time of purchase of the original system. Trade-in or upgrade transactions are based on the then fair value of the system and are separately negotiated taking into consideration circumstances existing at the time of the trade-in or upgrade. Accordingly, implied trade-ins and upgrades discounts are not considered separate performance obligations in system sales agreements. When systems are traded in, historically, the Company was able to recondition (re-new) the traded-in systems and resell them. In such transactions, the Company would estimate the stand-alone selling price of the traded-in system and include such amount as additional transaction price in the new bundled system sale. During fiscal year 2020, however, demand for reconditioned systems decreased, and no fair value has been assigned to any of the systems that were traded-in during fiscal year 2021 and 2022. These trade-in systems may be used for spare parts harvesting in certain cases. Such spare parts generally require reconditioning. The SSP of performance obligations is determined based on observable prices at which the Company separately sells the products and services. If the SSP is not directly observable, then the Company will estimate the SSP considering market conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The contract consideration allocation is based on the SSP at contract inception. The consideration (net of any discounts) is allocated among separate products and services in a bundle based on their relative SSPs. Contract modifications typically add additional goods or services or change pricing. For such modifications, the most recent SSP is used for reallocation to the remaining performance obligations. The Company recognizes revenue for certain performance obligations at the point in time when control is transferred, such as delivery of products and upgrades. Service revenue is recognized over the term of the service period as the customer benefits from the services throughout the service period. Revenue related to services that are not part of a service contract and performed on a time-and-materials basis are recognized when performed. Service contracts recognized over time comprise a single stand-ready performance obligation satisfied over time as our customers simultaneously receive and consume benefits from the Company's performance. This performance obligation constitutes a series of services that are substantially the same and provided over time using the same measure of progress. Revenues derived from these arrangements are recognized over time using an output method based upon the passage of time as this provides a faithful depiction of the pattern of transfer of control. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer when the Company expects to generate future economic benefits from the related revenue-generating contracts. The Company capitalizes incremental contract acquisition costs, and amortizes such costs over a five year period, the period which the Company expects to benefit, based on historical service renewal rates, and expectations of future customer renewals. Most of the Company’s contract costs are associated with its internal sales force compensation program and a portion of its employee bonus program. The Company capitalizes and amortizes the incremental costs of obtaining a contract, primarily related to certain bonuses and sales commissions. The capitalized bonuses and sales commissions are amortized over a period of five years commencing upon the initial transfer of control of the system to the customer. The pattern of amortization is commensurate with the pattern of transfer of control of the performance obligations to the customer. The amortization of these contract assets is included in cost of sales, research and development, sales and marketing, and general and administrative expenses based on department headcount allocations in the consolidated statements of operations. The Company elected to use the practical expedient and expense as incurred commissions related to service renewals and upgrades because the amortization period be one year or less. The Company invoices its customers based on the billing schedules in its sales arrangements. Payment terms vary from 30 to 90 days, or longer, from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms. Deferred revenue for periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to services being performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for any period presented. Deferred Revenue Deferred revenue primarily consists of unfulfilled obligations from open contracts for which performance has already started including short-shipped items, deferred warranty, training, maintenance services and other unperformed or incomplete performance obligations. Service contracts outside of the warranty period, for maintenance services, in general, are considered month-to-month contracts. Deferred revenue includes deferred warranty expected to be recognized over the remaining warranty period for system already installed. Customer Advances Customer advances represent payments made by customers in advance of product shipment. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight‑line method over the estimated useful lives of the related assets. Leasehold improvements are depreciated on a straight‑line basis over the remaining term of the lease or the estimated useful life of the asset, whichever is shorter. Machinery and equipment are depreciated over five years . Furniture and fixtures are depreciated over four years . Computer and office equipment and computer software are depreciated over three years . Repairs and maintenance costs, which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred. Software Capitalization Costs Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility. Impairment of Long‑Lived Assets The Company reviews long‑lived assets, including intangible assets, equity method investment in the JV, property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable using pretax undiscounted cash flows. Impairment, if any, is measured as the amount by which the carrying value of a long‑lived asset exceeds its fair value. Goodwill Goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. The Company has assessed that it has one operating segment and one reporting unit, and the consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. The Company estimates the fair value of the reporting unit based on the Company’s closing stock price on the trading day closest to the annual review date multiplied by the outstanding shares on that date. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the estimated fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required. The Company adopted the new accounting guidance that simplifies the testing for goodwill impairment in the first quarter of fiscal 2019. There was no impairment of goodwill identified in the fiscal years ended June 30, 2022, 2021 and 2020 . Shipping and Handling The Company’s billings for shipping and handling for product shipments to customers are included in cost of products. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of products. Advertising Expenses The Company expenses the costs of advertising and promoting its products and services as incurred. Advertising expenses were approximatel y $ 0.2 million, $ 0.2 million and $ 0.2 million for the years ended June 30, 2022, 2021 and 2020 , respectively, and are included in selling and marketing expense in the consolidated statements of operations. Research and Development Costs Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct compensation, benefits, and other headcount related costs for research and development personnel; costs for materials used in research and development activities; costs for outside services and allocated portions of facilities and other corporate costs. The Company has entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research institutions worldwide. These agreements support the Company’s internal research and development capabilities. Share‑Based Compensation The Company issues share‑based compensation awards to employees and directors in the form of stock options, restricted stock units (RSUs), performance units (PSUs), market stock units (MSUs) and employee stock purchase plan (ESPP) awards (collectively, awards). The exercise price of stock options granted is equal to the fair market value of the Company’s common stock on the date of grant. The Company measures and recognizes compensation expense for all stock‑based awards based on the awards’ fair value. Share‑based compensation for RSUs and PSUs is measured based on the value of the Company’s common stock on the grant date. The Company uses the Monte Carlo simulation model to estimate the grant date fair value of MSUs. Share‑based compensation for employee stock options and ESPP awards are measured on the date of grant using a Black‑Scholes option pricing model. Awards vest either on a vesting schedule or in a lump sum. The Company determines the fair value of each award as a single award and recognizes the expense on a straight‑line basis over the service period of the award, which is generally the vesting period. Stock options expire ten years from the date of grant. Share‑based compensation expense for stock options, RSUs, PSUs and the ESPP awards is based on awards ultimately expected to vest, and the expense is recorded net of estimated forfeitures. With respect to Performance Stock Units that are based on our corporate financial performance targets, or PSUs, the number of PSUs that will ultimately be awarded is contingent on the Company’s actual level of achievement compared to the corporate financial target performance targets. The Company recognizes expense for MSUs net of estimated forfeitures and does not adjust the expense for subsequent changes in the expected outcome of the market‑based vesting conditions. Loss Contingencies The Company is involved in various lawsuits, claims and proceedings that arise in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews these provisions quarterly and adjusts these provisions to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. Net Income (Loss) Per Common Share Basic and diluted net income (loss) per share is computed by dividing net income (loss) attributable to stockholders by the weighted average number of common shares outstanding during the year. Potentially dilutive outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share attributable to stockholders follows (in thousands): Years Ended June 30, 2022 2021 2020 Numerator: Net income (loss) used to compute basic and diluted loss $ ( 5,347 ) $ ( 6,311 ) $ 3,827 Denominator: Weighted average shares used to compute basic income (loss) 92,095 92,031 89,874 Weighted average shares used to compute diluted income (loss) 92,095 92,031 90,623 The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSU), Market Stock Units (MSU) and Performance Stock Units (PSU), and the purchase of shares under the Employee Stock Purchase Program (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net income (loss) per share when their effect would have been anti‑dilutive. Additionally, the outstanding 3.75 % Convertible Notes due July 2022 (the “ 3.75 % Convertible Notes due 2022”) and the 3.75 % Convertible Notes due June 2026 (the “ 3.75 % Convertible Notes due 2026” and together with the 3.75 % Convertible Notes due 2022, the “Notes”) are included in the calculation of diluted net income per share only if their inclusion is dilutive for periods during which the notes were outstanding. The following table sets forth all potentially dilutive securities excluded from the computation in the table above when their effect would have been anti‑dilutive (in thousands): As of June 30, 2022 2021 2020 Stock options 7,053 7,030 5,956 RSUs, PSUs and MSUs 5,775 3,198 3,761 12,828 10,228 9,717 Outstanding Convertible Notes—Diluted Share Impact Due to the optional cash settlement feature and management’s intent to settle the principal amount thereof in cash, the shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75 % Convertible Notes due 2022 and 3.75 % Convertible Notes due 2026 outstanding as of June 30, 2022, totaling approximately 0.5 million s hares and 17.1 million shares of the Company’s common stock, respectively, as of June 30, 2022, the effect of adding the shares were antidilutive and were not included in the basic and diluted net loss per common share table above. The shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75 % Convertible Notes due 2022 outstanding as of June 30, 2021 and 2020, totaled approximately 0.5 million and 14.9 million shares, respectively, of the Company’s common stock and the effect of adding the shares were antidilutive and were not included in the basic and diluted net income (loss) per common share table above. Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statements of operations. The Company determines the lease term by agreement with lessor, including lease renewal and extension. As the leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Equity Method Investment In 2020, the Company adopted a new accounting policy related to equity method investments in connection with its equity investment in CNNC Accuray (Tianjin) Medical Technology Co. Ltd., the Company’s joint venture in China (the “JV”). The equity method investment that the Company holds in the JV for which the Company has the ability to exercise significant influence over the JV but lacks a controlling financial interest in the JV. The equity method investment is measured at cost and adjusted for impairment, if any, for the Company’s share of the JV's income or loss and intra-entity profits. The Company recognizes its proportionate share of income or loss from the JV on a one-quarter lag due to the timing of the availability of the JV’s financial records. Profit earned by the Company from the JV is eliminated through cost of goods sold until it is realized; such profits would generally be considered realized when the inventory has been sold through to third parties . Equity method goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. Our impairment analysis considers qualitative and quantitative factors that may have a significant impact on the JV's fair value. Qualitative factors include the investee's financial condition and business outlook, industry and sector performance, operational and financing cash flow activities, and other relevant factors affecting the JV. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments, which require judgment and the use of estimates, including discount rates, investee revenue and costs, and comparable market data, among others. Income Taxes The Company is required to estimate its income taxes in each of the tax jurisdictions in which it operates prior to the completion and filing of tax returns for such periods. This process involves estimating actual current tax expense together with assessing temporary diff

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Note 2. Recent Accounting Pronouncements Accounting Pronouncement Recently Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). Under ASU No. 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments when calculating diluted earnings per share. The Company adopted this standard effective July 1, 2021, using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The Company applied the provisions of this guidance to our 3.75 % convertible senior notes due June 2026 (“2026 Notes”). Upon adoption, the Company recorded an increase to Accumulated deficit of $ 0.8 million, a decrease to Additional paid-in capital of $ 25.6 million and an increase to Debt of $ 24.8 million. There was no impact to diluted loss per share as the inclusion of potential shares of common stock related to the 2026 Notes would have been anti-dilutive. For further information, see Note 10, Debt. Accounting Pronouncements Not Yet Effective In March 2020, the FASB issued an update (ASU 2020-04) establishing Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company’s New Term Loan Facility and New Revolving Credit Facility applies Eurodollar rate LIBOR to the variable component of the interest rate, if a Benchmark transition event, or an early opt-in election, as applicable occurred a transition to the use of the Secured Overnight Financing Rate ("SOFR") to replace such rate. This accounting standard update was effective upon issuance and may be applied prospectively through December 31, 2022. The Company is currently evaluating the impact of the guidance and our options related to the practical expedients. In April 2021, the FASB issued ASU 2021-04, which included Topic 260 “Earnings Per Share”. This guidance clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. The ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2021-04 on its consolidated financial statements. In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendment addresses how to account for contract assets recognized under Topic 606 in a business combination. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact ASU 2021-08 will have on its financial statements.

Revenue

Revenue	12 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Note 3. Revenue Contract Balances The timing of revenue recognition, billings, and cash collections results in trade receivables, unbilled receivables, and deferred revenues on the consolidated balance sheets. The Company may offer longer or extended payments of more than one year for qualified customers in some circumstances. At times, revenue recognition occurs before the billing, resulting in an unbilled receivable, which represents a contract asset. The contract asset is a component of accounts receivable and other assets for the current and non-current portions, respectively. When the Company receives advances or deposits from customers before revenue is recognized, this results in a contract liability. It can take up to two and half years from the time of order to revenue recognition due to the Company’s long sales cycle. Changes in the contract assets and contract liabilities are as follows: June 30, June 30, Change (Dollars in thousands) Amount Amount $ % Assets: Unbilled accounts receivable – current (1) $ 13,325 $ 12,354 971 8 Interest receivable – current (2) 493 512 ( 19 ) ( 4 ) Long-term accounts receivable (3) 5,301 4,970 331 7 Interest receivable – non-current (3) 683 1,083 ( 400 ) ( 37 ) Liabilities: Customer advances 25,290 24,937 353 1 Deferred revenue – current 75,375 81,660 ( 6,285 ) ( 8 ) Deferred revenue – non-current 24,694 23,685 1,009 4 (1) Included in accounts receivable on consolidated balance sheets (2) Included in prepaid expenses and other current assets on consolidated balance sheets (3) Included in other assets on consolidated balance sheets During the years ended June 30, 2022 and June 30, 2021, the Company recognized revenues of $ 81.2 million and $ 107.3 million, respectively, which were included in the deferred revenue balances at June 30, 2021 and June 30, 2020, respectively. Remaining Performance Obligations Remaining performance obligations represent deferred revenue from open contracts for which performance has already started and the transaction price from executed contracts for which performance has not yet started. Service contracts in general are considered month-to-month contracts. As of June 30, 202 2, total remaining performance obligations amounted to $ 1,104.4 million. Of this total amount, $ 69.1 million related to long-term warranty and service, such as non-cancellable post contract services and system warranty, which is expected to be recognized over the remaining service period and warranty period for systems that have been delivered, respectively. The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post warranty services as of June 30, 2022 and the estimated revenue expected to be recognized (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products). The Company has elected the practical expedient to not disclose the unsatisfied performance obligations of contracts with an original expected duration of one year or less. Fiscal years of revenue recognition (Dollars in thousands) 2023 2024 2025 Thereafter Long-term warranty and service $ 30,741 $ 20,491 $ 9,071 $ 8,797 For the remaining $ 1,035.3 million of performance obligations (open systems sales, upgrades, training and other miscellaneous items), the Company estimates 25 % to 28 % will be recognized in the next 12 months, and the remaining portion will be recognized thereafter. The Company’s historical experience indicates that some of its customers will cancel or renegotiate contracts as economic conditions change or when product offerings change during the long sales cycle. The Company anticipates a portion of its open contracts may never result in revenue recognition primarily due to the long sales cycle and factors outside of its control including changes in customers' needs or financial condition, changes in government or health insurance reimbursement policies or changes to regulatory requirements. Based on historical experience and management's best estimate, approximately 16 % of the Company’s $ 983.2 million open system sales contracts may never result in revenue. Capitalized Contract Costs As of June 30, 2022 and 2021, the balance of capitalized costs to obtain a contract was $ 11.4 million and $ 8.9 million, respectively. The Company has classified the capitalized costs to obtain a contract as a component of prepaid expenses and other current assets and other assets with respect to the current and non-current portions of capitalized costs, respectively, on the consolidated balance sheets. The Company incurred a $ 0.6 million and $ 0.6 million impairment loss for the years ended June 30, 2022 and 2021, respectively. During the years ended June 30, 2022 and 2021 the Company recognized $ 3.3 million and $ 2.8 million, respectively, in expense related to the amortization of the capitalized contract costs.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Jun. 30, 2022
Supplemental Financial Information Disclosure [Abstract]
Supplemental Financial Information	Note 4. Supplemental Financial Information Consolidated Balance Sheet Accounts receivable, net Accounts receivable, net consisted of the following (in thousands): June 30, June 30, Accounts receivable $ 82,117 $ 74,054 Unbilled fees and services 13,325 12,354 95,442 86,408 Less: Allowance for credit losses ( 1,000 ) ( 1,048 ) Accounts receivable, net $ 94,442 $ 85,360 The Company received payme nt or had credits of $ 0.3 million, added $ 0.6 million and wrote off $ 0.3 million from the allowance for credit losses in fiscal 2022. The Company received payment or had credits of $ 0.8 million, added $ 0.7 million and wrote off $ 0.2 million from the allowance for credit losses in fiscal 2021. Financing receivables A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset in the Company’s balance sheet. The Company’s financing receivables, with contractual maturities of more than one year, totaled $ 2.8 million and $ 3.4 million at June 30, 2022 and 2021, respectively, and are included in Other Assets in the consolidated balance sheets. The Company evaluates the credit quality of a customer at contract inception and monitors credit quality over the term of the underlying transactions. The Company performs a credit analysis for all new customers and reviews payment history, current order backlog, financial performance of the customers and other variables that augment or mitigate the inherent credit risk of a particular transaction. Such variables include the underlying value and liquidity of the collateral, the essential use of the equipment, the contract term and the inclusion of credit enhancements, such as guarantees, letters of credit or security deposits. The Company classifies accounts as high risk when it considers the financing receivable to be impaired or when management believes there is a significant near‑term risk of non‑payment. The Company performed an assessment of the allowance for credit losses related to its financing receivables. Based upon such assessment, the Company recorded adjustments of zero and $ 3.4 million to the allowance for credit losses related to such financing receivables during the years ended June 30, 2022 and 2021, respectively. A summary of the Company’s financing receivables is presented as follows (in thousands): June 30, 2022 June 30, 2021 Financing receivable $ 6,137 $ 7,102 Allowance for credit losses ( 943 ) ( 943 ) Total, net $ 5,194 $ 6,159 Reported as: Current $ 2,435 $ 2,772 Non-current 2,759 3,387 Total, net $ 5,194 $ 6,159 The Company added and wrote off no amount f rom the allowance for credit losses in fiscal year 2022. The Company added $ 0.2 million and wrote off $ 3.6 million in fiscal year 2021. Actual cash collections may differ from the contracted maturities due to early customer buyouts, refinancing, or defaults. Inventories Inventories consisted of the following (in thousands): June 30, June 30, Raw materials $ 61,871 $ 45,301 Work-in-process 16,367 22,014 Finished goods 64,016 58,614 Inventories $ 142,254 $ 125,929 Property and Equipment, net Property and equipment consisted of the following (in thousands): June 30, June 30, Furniture and fixtures $ 1,766 $ 1,636 Computer and office equipment 8,605 8,972 Software 5,344 7,477 Leasehold improvements 26,659 26,102 Machinery and equipment 46,522 45,265 Construction in progress 2,999 1,055 91,895 90,507 Less: Accumulated depreciation ( 79,210 ) ( 78,175 ) Property and equipment, net $ 12,685 $ 12,332 Depreciation and amortization expense related to property and equipment for the years ended June 30, 2022, 2021 and 2020 was $ 5.4 million, $ 6.2 million and $ 7.3 million, respectively. Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands): Foreign Change in Total Balance at June 30, 2020 $ 752 $ ( 1,236 ) $ ( 484 ) Other comprehensive loss 1,705 872 2,577 Balance at June 30, 2021 $ 2,457 $ ( 364 ) $ 2,093 Other comprehensive loss ( 3,998 ) 4,311 313 Balance at June 30, 2022 $ ( 1,541 ) $ 3,947 $ 2,406 Consolidated Statements of Operations Other expense, net consisted of the following (in thousands): Years Ended June 30, (in thousands) 2022 2021 2020 Interest expense $ ( 8,129 ) $ ( 16,893 ) ( 18,080 ) Foreign currency transaction loss ( 2,618 ) ( 1,953 ) ( 2,343 ) Gain on contribution to joint venture — — 12,964 Loss on Debt Extinguishment — ( 9,948 ) — Other expense, net 356 1,128 759 Total other expense, net $ ( 10,391 ) $ ( 27,666 ) $ ( 6,700 )

Leases

Leases	12 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Note 5. Leases The Company has operating leases for corporate offices and warehouse facilities worldwide. Additionally, the Company leases cars, copy machines and laptops that are considered operating leases. Some of the Company's leases are non-cancellable operating lease agreements with various expiration dates through September 2026. Certain lease agreements include options to renew or terminate the lease, which are not reasonably certain to be exercised and therefore are not factored into the determination of lease payments. Operating lease costs for the twelve mon ths ended June 30, 2022 and 2021 were $ 9.2 million and $ 9.1 million, respectively, not including short-term operating lease costs for the twelve months ended June 30, 2022 and 2021 of $ 0.4 million and $ 0.2 million, respectively. For the twelve months ended June 30, 2022 and 2021, cash paid for amounts included in the measurement of operating lease liabilities was approximately $ 9.8 million and $ 9.7 million, respectively. Operating lease liabilities arising from obtaining operating right-of-use assets totaled $ 3.2 million and $ 1.1 million, respectively for the years ended June 30, 2022 and 20 21. Operating lease right-of-use assets and operating lease obligation are represented in the table below (in thousands): June 30, June 30, Beginning balance operating lease right-of-use asset $ 22,522 $ 28,647 Lease asset added 3,522 1,069 Amortization for the year ( 9,246 ) ( 7,194 ) Ending balance operating lease right-of-use asset $ 16,798 $ 22,522 Beginning balance operating lease obligation $ 25,609 $ 32,397 Lease liability added 3,209 1,069 Repayment and interest accretion ( 9,798 ) ( 7,857 ) Ending balance operating lease obligation $ 19,020 $ 25,609 Current portion of operating lease obligation $ 8,567 $ 8,169 Noncurrent portion of operating lease obligation $ 10,453 $ 17,441 Maturities of operating lease liabilities as of June 30, 2022 are presented in the table below (in thousands) : Year Ending June 30, Amount 2023 $ 9,554 2024 6,770 2025 3,631 2026 354 2027 197 Total operating lease payments 20,506 Less: imputed interest ( 1,486 ) Present value of operating lease liabilities $ 19,020 The weighted average remaining lease term for the Company’s operating leases was 2.59 years and the weighted average discount rate was 6.07 % as of Jun e 30, 2022.

Goodwill and Purchased Intangib

Goodwill and Purchased Intangible Assets	12 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Purchased Intangible Assets	Note 6. Goodwill and Purchased Intangible Assets Goodwill Goodwill as of June 30, 2022 and 2021 and changes in the carrying amount of goodwill for the respective periods are as follows (in thousands): As of June 30, 2022 2021 Balance at the beginning of the period $ 57,960 $ 57,717 Currency translation adjustment ( 120 ) 243 Balance at the end of the period $ 57,840 $ 57,960 In fiscal year 2022, the Company performed its annual goodwill impairment test and determined that there was no impairment to goodwill. The Company will continue to monitor its recorded goodwill for indicators of impairment. Purchased Intangible Assets The Company’s intangible assets associated with purchased patent license are as follows (in thousands): As of June 30, 2022 As of June 30, 2021 Useful Gross Accumulated Net Gross Accumulated Net (in years) Patent license 2 - 7 $ 1,170 $ ( 920 ) $ 250 $ 1,170 $ ( 735 ) $ 435 During fiscal year 2017, the Company purchased a patent license with a useful life of seven years . During the fiscal year 2020, the Company purchased a patent license for $ 0.2 million with a useful life of two years . The Company did not identify any triggering events that would indicate potential impairment of its definite‑lived intangible and long‑lived assets as of June 30, 2022 and 2021. Amortization expense related to purchased intangible assets was $ 0.1 million, $ 0.2 million and $ 0.2 million for the years ended June 30, 2022, 2021 and 2020, respectively. The estimated future amortization expense of purchased intangible assets as of June 30, 2022 is as follows (in thousands): Year Ending June 30, Amount 2023 $ 143 2024 107 $ 250

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 7. Derivative Financial Instruments The Company utilizes foreign currency forward contracts with reputable financial institutions to manage its exposure of fluctuations in foreign currency exchange rates on certain intercompany balances and foreign currency denominated cash, customer receivables and liabilities. The Company does not use derivative financial instruments for speculative or trading purposes. These forward contracts are not designated as hedging instruments for accounting purposes. Principal hedged currencies include the Euro, Japanese Yen, Swiss Franc, and U.S. Dollar. The periods of these forward contracts range up to approximately three months and the notional amounts are intended to be consistent with changes in the underlying exposures. The Company intends to exchange foreign currencies for U.S. Dollars at maturity. The Company enters into forward currency exchange contracts to hedge its overseas operating expenses and other liabilities when deemed appropriate. As of June 30, 2022 and 2021, the Company had the following outstanding forward currency exchange contracts (in notional amount): As of June 30, (In thousands and U.S. dollars) 2022 2021 Canadian Dollar $ — $ 527 Swiss Franc 27,910 8,891 Chinese Yuan 2,524 1,927 Euro 16,307 19,037 British Pound 3,699 3,191 Indian Rupee 3,728 7,825 Japanese Yen 14,167 12,803 $ 68,335 $ 54,201 The Company entered into the foreign exchange forward contracts on June 30, 2022 and June 30, 2021, respectively, and therefore, there was no amount recorded on the balance sheets. The following table provides information about gain (loss) associated with the Company’s derivative financial instruments (in thousands): Years ended June 30, 2022 2021 2020 Foreign currency exchange gain (loss) on forward contracts $ ( 2,045 ) $ ( 2,349 ) $ 744 Foreign currency transactions gain (loss) ( 887 ) 396 ( 3,087 )

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8. Fair Value Measurements Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows: Level 1— Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date. Level 2— Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets in non-active markets; • Inputs other than quoted prices that are observable for the asset or liability; and • Inputs that are derived principally from or corroborated by other observable market data. Level 3— Unobservable inputs that cannot be corroborated by observable market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. Assets and Liabilities That Are Measured at Fair Value At June 30, 2022, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated, or notional, value of approximately $ 68.3 million. The fair value of the forward contract based upon the June 30, 2022 exchange rate was approximately $ 68.3 million, which it considers to be a Level 2 fai r value measurement. At June 30, 2021, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated, or notional, value of approximately $ 54.2 million. The fair value of the forward contract based upon the June 30, 2021 exchange rate was approximately $ 54.2 million, which it considers to be a Level 2 fair value measurement. The Company’s debt is measured on a recurring basis using Level 2 inputs based upon observable inputs of the Company’s convertible debt. The Revolving Credit Facility (as defined below) and the Term Loan (as defined below) reflects the bank quoted market, which the Company considers to be a Level 2 fair value measurement. The Company believes that the carrying value of these financial instruments approximate its estimated fair value based on the effective interest rate compared to the current market rate available to the Company and analyzed at quarter-end. The following table summarizes the carrying value and estimated fair value of the Term Loan, the Revolving Credit Facility, the 3.75 % Convertible Notes due 2022 and the 3.75 % Convertible Notes due 2026 (in thousands): June 30, 2022 June 30, 2021 Carrying Fair Value Carrying Fair Value 3.75 % Convertible Notes Due 2022 $ 2,863 $ 2,729 $ 2,712 $ 3,164 3.75 % Convertible Notes Due 2026 97,619 78,561 72,388 108,163 Term Loan Facility 74,988 74,988 78,697 78,697 Revolving Credit Facility 5,000 5,000 20,000 20,000 Total $ 180,470 $ 161,278 $ 173,797 $ 210,024

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Long‑term Debt Commitments The Company is required to make semi‑annual interest payments on the 3.75 % Convertible Notes due 2022 and 3.75 % Convertible Notes due 2026, and monthly interest payments on the New Revolving Credit Facility and New Term Loan Facility. See Note 10, Debt , for details. Future minimum long‑term principal and interest on the Notes and New Credit Facilities (as defined below), including short-term portion, as of June 30, 2022 are as follows (in thousands): Year Ending June 30, Long-Term 2023 $ 16,266 2024 13,138 2025 14,827 2026 116,777 Total $ 161,008 (1) These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company’s consolidated balance sheet. Any conversion, premium, redemption or purchase of the Notes that would impact cash payments noted in the preceding table. Purchase Commitments The Company’s purchase commitments and obligations include all open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers, for which the Company has not received the goods or services and acquisition and licensing of intellectual property. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allows the Company the option to cancel, reschedule, and adjust its requirements based on the Company’s business needs prior to the delivery of goods or performance of services, and hence, these purchase orders have not been included in the table above. Indemnities and Commitments The Company enters into standard indemnification agreements with its landlords and all superior mortgagees and their respective directors, officers’ agents, and employees in the ordinary course of business. Pursuant to these agreements, the Company will indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the landlords, in connection with any loss, accident, injury, or damage by any third‑party with respect to the leased facilities. The term of these indemnification agreements is from the commencement of the lease agreements until termination of the lease agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, historically the Company has not incurred claims or costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has not recorded any liability associated with its indemnification agreements as it is not aware of any pending or threatened actions that represent probable losses as of June 30, 2022. Guarantees As of June 30, 2022 and June 30, 2021, the Company had various bank guarantees totaling approximately $ 1.2 million and $ 1.2 million, respectively, related to a bidding process with customers. Royalty Agreement The Company enters into software license agreements with third parties that may require royalty payments for each license used. In connection with such agreements, the Company recorded royalty costs o f $ 1.9 million, $ 1.9 million and $ 2.5 million for the years ended June 30, 2022, 2021 and 2020 , respectively, which were recorded in cost of revenue or deferred cost of revenue. The Company had approximately $ 2.4 million and $ 2.3 million accrued liabilities at June 30, 2022 and 2021, respectively, related to this agreement. Software License Indemnity Under the terms of the Company’s software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third‑party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of June 30, 2022. Litigation From time to time, the Company is involved in legal proceedings arising in the ordinary course of its business. The Company records a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. Currently, management believes the Company does not have any probable and reasonably estimable losses related to any current legal proceedings and claims. Although occasional adverse decisions or settlements may occur, management does not believe that an adverse determination with respect to any of these claims would individually or in the aggregate materially and adversely affect the Company’s financial condition or operating results. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position, and cash flows.

Debt

Debt	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	Note 10. Debt 3.75% Convertible Senior Notes due July 2022 In August 2017, the Company issued $ 85.0 million aggregate principal amount of its 3.75 % Convertible Senior Notes due 2022 (the “ 3.75 % Convertible Notes due 2022”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. $ 53.0 million aggregate principal amount of the 3.75 % Convertible Notes due 2022 were issued to certain holders of the Company’s then outstanding 3.50 % Convertible Notes due 2018 and 3.50 % Series A Convertible Notes due 2018 (together, the “Prior Existing Notes”) in exchange for approximately $ 47.0 million aggregate principal amount of the Prior Existing Notes and $ 32.0 million aggregate principal amount of the 3.75 % Convertible Notes due 2022 were issued to certain other qualified new investors for cash. The net proceeds of the cash issuance were used to repurchase approximately $ 28.0 million of Prior Existing Notes. Holders of the 3.75 % Convertible Notes due 2022 did not convert their notes at any time and was repaid in cash subsequent to June 30, 2022. Upon conversion, the Company will have the right to pay cash, or deliver shares of common stock of the Company or a combination thereof, at the Company’s election. The initial conversion rate is 174.8252 shares of the Company’s common stock per $ 1,000 principal amount (which represents an initial conversion price of approximately $ 5.72 per share of the Company’s common stock). The conversion rate, and thus the conversion price, is subject to adjustment as further described below. Holders of the 3.75 % Convertible Notes due 2022 who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.75 % Convertible Notes due 2022 may require the Company to purchase all or a portion of their note at a fundamental change repurchase price equal to 100 % of the principal amount of the 3.75 % Convertible Notes due 2022, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. In May 2021, the Company exchanged approximately $ 82.1 million aggregate principal amount of 3.75 % Convertible Notes due 2022 for approximately $ 97.1 million aggregate principal amount of 3.75 % Convertible Notes due 2026 (as defined below). As of June 30, 2022 and June 30, 2021, $ 2.9 million aggregate principal amount of 3.75 % Convertible Notes due 2022 remained outstanding. The exchange was treated as extinguishment of debt. The Company recorded a loss on the extinguishment of debt of $ 4.3 million, primarily comprised of the write-off of deferred costs associated with the 3.75 % Convertible Notes due 2022. The extinguishment of the equity component of $ 14.5 million was recognized as reduction to additional paid in capital. The $ 14.5 million is the difference between the settlement consideration paid of $ 96.0 million and the fair value of the liability component of $ 81.5 million. 3.75% Convertible Senior Notes due July 2026 In May 2021, the Company issued $ 100.0 million aggregate principal amount of its 3.75 % Convertible Senior Notes due 2026 (the “ 3.75 % Convertible Notes due 2026”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. $ 97.1 million aggregate principal amount of the 3.75 % Convertible Notes due 2026 were issued to certain holders of the Company’s outstanding 3.75 % Convertible Notes due 2022 in exchange for approximately $ 82.1 million aggregate principal amount of 3.75 % Convertible Notes due 2022 and $ 2.9 million of 3.75 % Convertible Notes due 2026 were issued to certain other qualified new investors for cash (such transactions the “Exchange and Subscription Transactions”). Holders of the 3.75 % Convertible Notes due 2026 may convert their notes at any time on or after March 6, 2026 until the close of the business day immediately preceding the maturity date. Prior to June 6, 2026, holders of the 3.75 % Convertible Notes due 2026 may convert their notes only under certain circumstances. Upon conversion, the Company will have the right to pay cash, or deliver shares of common stock of the Company or a combination thereof, at the Company’s election. The initial conversion rate is 170.5611 shares of the Company’s common stock per $ 1,000 principal amount (which represents an initial conversion price of approximately $ 5.86 per share of the Company’s common stock). The conversion rate, and thus the conversion price, is subject to adjustment as further described below. Holders of the 3.75 % Convertible Notes due 2026 who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.75 % Convertible Notes due 2026 may require the Company to purchase all or a portion of their note at a fundamental change repurchase price equal to 100 % of the principal amount of the 3.75 % Convertible Notes due 2026, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. As of June 30, 2022 and June 30, 2021, $ 100.0 million aggregate principal amount of 3.75 % Convertible Notes due 2026 was outstanding. The aggregate principal amount of $ 100.0 million, including $ 2.9 million which were issued to new qualified investors for cash in the 3.75 % Convertible Notes due 2026, was allocated between liability component of $ 74.1 million and equity component of $ 25.9 million recognized as addition paid in capital, reduced by $ 0.7 million of 3.75 % Convertible Notes due 2026 issuance cost allocated to additional paid in capital. Upon adoption of ASU No. 2020-06 on July 1, 2021, the Company recorded an increase to Accumulated deficit of $ 0.8 million, a decrease to Additional paid-in capital of $ 25.6 million, an increase to Debt, current of $ 24.8 million. There was no impact to diluted loss per share as the inclusion of potential shares of common stock related to the 3.75 % Convertible Notes due 2026 would have been anti-dilutive. The Company reversed the separation of the debt and equity components and accounted for the 3.75 % Convertible Notes due 2026 wholly as debt. The Company also reversed the amortization of the debt discount, with a cumulative adjustment to retained earnings on the adoption date. Debt issuance costs related to the 3.75 % Convertible Notes due 2022 and the 3.75 % Convertible Notes due 2026 were comprised of discounts, issuance costs and third party costs of $ 25.6 million. Prior to the adoption of ASU No. 2020-06, the Company allocated the total amount incurred to the liability and equity components of the 3.75 % Convertible Notes due 2022 and the 3.75 % Convertible Notes due 2026 based on their relative values. Issuance costs attributable to the liability component were $ 0.8 million and were amortized to interest expense using the effective interest method. Issuance costs attributable to the equity component were netted with the equity component in stockholders’ equity. Upon adoption of ASU No. 2020-06 on July 1, 2021, the Company reversed the allocation of the issuance costs to the equity component and accounted for the entire amount as debt issuance cost that will be amortized as interest expense for each of the respective terms of the 3.75% Convertible Notes due 2022 and the 3.75% Convertible Notes due 2026, respectively, with a cumulative adjustment to retained earnings on the adoption date. As of June 30, 2022, the if-converted value of the 3.75% Convertible Notes due 2022 and the 3.75% Convertible Notes due 2026 did not exceed the outstanding principal amount. Prior Revolving Credit Facility On June 14, 2017, the Company entered into a credit and security agreement with a lender (the “Prior Credit Agreement”). The Prior Credit Agreement provided the Company with a revolving credit facility in the initial amount of $ 52.0 million (the “Prior Revolving Credit Facility”). Availability for borrowings under the Prior Revolving Credit Facility was subject to a borrowing base that was calculated as a function of the value of the Company’s eligible accounts receivable and eligible inventory, and the Company was required to maintain a minimum drawn balance of at least 30 % of such availability. Interest on the borrowings under the Prior Revolving Credit Facility was payable monthly in arrears at an annual interest rate of reserve-adjusted, 90-day LIBOR plus 4.50 % and had initial maturity date of June 14, 2021. In December 2017, concurrently with the Prior Term Loan Agreement (as defined below), the Company entered into an amendment to the Credit Agreement (the “Prior Amendment” and, collectively with the Prior Credit Agreement, the “Amended Prior Credit Agreement”). The Prior Amendment reduced the maximum borrowings under the Prior Revolving Credit Facility to $ 32.0 million and extended the maturity date of the Prior Revolving Credit Facility to December 15, 2022. In May 2019, the Company amended the Amended Prior Credit Agreement to, among other things, decrease the interest rate from 90-day LIBOR plus 4.50 % to 90-day LIBOR plus 3.50 % and extend the maturity date to May 30, 2024 and update the calculation of the deferred revolving loan origination fee such that it is based on the amount of time elapsed from the effective date of the May 2019 amendment. The Company accounted for the amendment as a modification of existing debt and deferred an insignificant amount of offering costs on the consolidated balance sheet as of June 30, 2019. The Amended Prior Credit Agreement was further amended in August 2019 to, among other things, revise or add financial covenants, including the fixed charge coverage ratio, minimum net revenue, minimum consolidated cash balance and minimum consolidated domestic cash balance tests. Other significant terms remained unchanged. The Company accounted for the amendment as a modification of existing debt and deferred an insignificant amount of offering costs on the consolidated balance sheet. On May 6, 2021, the Company entered into an amendment to the Amended Prior Credit Agreement to amend the Prior Revolving Credit Facility to, among other things and subject to certain conditions, permit the Company to consummate the Exchange and Subscription Transactions and related agreements. On May 14, 2021, the initial borrowings under the New Credit Agreement (as defined below), plus available cash on hand, were used to repay all outstanding obligations and terminate all commitments under the Amended Prior Credit Agreement. The Prior Revolving Credit Facility was terminated on May 14, 2021. The Company incurred a loss on the extinguishment of debt as a result of repaying all amounts outstanding on the Prior Revolving Credit Facility. The loss on the extinguishment of debt of $ 1.4 million was primarily comprised of the write-off of deferred costs associated with the Prior Credit Facilities. Prior Term Loan In December 2017, the Company entered into a credit and security agreement with a lender (the “Prior Term Loan Agreement”). The Prior Term Loan Agreement provided for an initial term loan of $ 40.0 million with an additional tranche of $ 20.0 million undrawn and available through December 31, 2018, if specified conditions were met (the “Prior Term Loan”). In connection with the Prior Amendment, the Company used a portion of the net proceeds from the initial advance to repay a portion of the outstanding borrowings under the Prior Revolving Credit Facility. Interest on the Prior Term Loan was payable monthly in arrears at an annual interest rate of 6.75 % plus 90-day LIBOR . The Prior Term Loan Agreement would have matured December 15, 2022 and, if prepaid, had fees equal to 3 %, 2 %, and 1 % of the prepayment amount if such termination occurred within the first year, the second year, and the third year of funding, respectively. The term of the loan was 60 months with interest only for the first 24 months followed by straight-line amortization of principal for the remaining months. In addition, the Company paid an annual administrative fee of 0.25 % and a final payment of 4.0 % of the Prior Term Loan amount. In December 2018, the Company drew an additional $ 5.0 million under the Prior Term Loan Agreement and in connection therewith entered into the second amendment to the Prior Term Loan Agreement (“Prior Amendment 2”) which, among other things, (i) extended the term loan tranche 2 commitment termination date for the remaining $ 15.0 million unfunded commitment from December 31, 2018 to June 30, 2019 ; (ii) provided that term loan tranche 2 may be drawn in two separate advances; and (iii) updated the calculation of the prepayment fee such that it is based on the amount of time elapsed from the effective date of Prior Amendment 2. In May 2019, the Company amended the Prior Term Loan Agreement to, among other things, increase the loan tranche 2 commitment by $ 0.5 million, extend the maturity date to May 30, 2024, decrease the annual interest rate from 6.75 % plus 90-day LIBOR to 5.50 % plus 90-day LIBOR , and modify the calculation prepayment fee such that it is based on the amount of time elapsed from the effective date of the May 2019 amendment. The Company accounted for the amendment as a modification of existing debt and recorded approximately $ 1.5 million of debt discount costs associated with the amendment against long-term debt on the consolidated balance sheets as of June 30, 2019. In August 2019, the Company amended the Prior Term Loan Agreement to, among other things, increase the loan commitment by $ 25 million in the form of a new tranche (“Tranche 3”), increase the annual interest rate from 5.50 % plus 90-day LIBOR to 6.75 % plus 90-day LIBOR , and revise or add financial covenants, including the fixed charge coverage ratio, minimum net revenue, minimum consolidated cash balance and minimum consolidated domestic cash balance tests. Other significant terms remain unchanged. The Company borrowed in full Tranche 3, or $ 25 million, on the date of the amendment. The Company accounted for the amendment as a modification of existing debt, at the same time, the Company recorded approximately $ 1.6 million of debt discount costs associated with the amendment against long-term debt. On May 6, 2021, the Company entered into an amendment to the Prior Term Loan Agreement to amend the Prior Term Loan Facility to, among other things and subject to certain conditions, permit the Company to consummate the Exchange and Subscription Transactions and related agreements. On May 14, 2021, the initial borrowings under the New Credit Agreement (as defined below), plus available cash on hand, were used to repay all outstanding obligations and terminate all commitments under the Prior Term Loan Agreement. The Prior Term Loan Facility was terminated on May 14, 2021. The Company incurred a loss on the extinguishment of debt as a result of repaying all amounts outstanding on the Prior Term Loan Facility. The loss on the extinguishment of debt of $ 4.3 million was primarily comprised of the write-off of deferred costs associated with the Prior Credit Facilities. New Credit Facilities On May 6, 2021, the Company entered into a senior secured credit agreement (the “New Credit Agreement”) with Silicon Valley Bank, individually as a lender and agent (“Agent”), and the other lenders from time to time parties thereto (together with Silicon Valley Bank as a lender, the “Lenders”), which provides for a new five-year $ 80 million term loan (the “New Term Loan Facility”) and a $ 40 million revolving credit facility (the “New Revolving Credit Facility” and, together with the New Term Loan Facility, the “New Credit Facilities”). The initial borrowings under the New Credit Agreement, including $ 25 million under the New Revolving Credit Facility, were funded on May 14, 2021. Interest on the borrowings under the New Credit Facilities is payable in arrears on the applicable interest payment date at an annual interest rate of reserve-adjusted, 90-day LIBOR (subject to a 0.50 % floor) plus, initially, 3.00 % and after the Agent receives copies of the consolidated financial statements of the Company for the fiscal quarter ending June 30, 2021: 3.25 % if the Consolidated Senior Net Leverage Ratio (as defined in the New Credit Agreement) is greater than or equal to 3.00:1.00; 3.00 % if the Consolidated Senior Net Leverage Ratio is greater than or equal to 2.00:1.00 but less than 3.00:1.00; 2.75 % if the Consolidated Senior Net Leverage Ratio is greater than or equal to 1.00:1.00 but less than 2.00:1.00; and 2.50 % if the Consolidated Senior Net Leverage Ratio is less than 1.00:1.00. The New Credit Agreement requires the Company to pay the Lenders an unused commitment fee equal to, initially, 0.35 % per annum of the average unused portion of the New Revolving Credit Facility and after the Agent receives copies of the consolidated financial statements of the Company for the fiscal quarter ending June 30, 2021: 0.40 % per annum of the average unused portion of the Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is greater than or equal to 3.00:1.00; 0.35 % per annum of the average unused portion of the New Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is greater than or equal to 2.00:1.00 but less than 3.00:1.00; 0.30 % per annum of the average unused portion of the New Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is greater than or equal to 1.00:1.00 but less than 2.00:1.00; and 0.25 % per annum of the average unused portion of the New Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is less than 1.00:1.00. If all or a portion of the loans under the New Term Loan Facility are prepaid, then the Company will be required to pay a fee equal to 1 % of the of the aggregate amount of the loans so prepaid, subject to certain exceptions. The New Credit Agreement contains restrictions and covenants applicable to the Company and its subsidiaries. Among other requirements, the Company may not permit the Fixed Charge Coverage Ratio (as defined in the New Credit Agreement) to be less than a certain specified ratio for each fiscal quarter during the term of the New Credit Agreement or the Consolidated Senior Net Leverage Ratio to be greater than a certain specified ratio for each fiscal quarter during the term of the New Credit Agreement. The New Credit Agreement also contains customary covenants that limit, among other things, the ability of the Company and its subsidiaries to (i) incur indebtedness, (ii) incur liens on their property, (iii) pay dividends or make other distributions, (iv) sell their assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. The New Credit Agreement contains customary representations and warranties and events of default. As of June 30, 2022, $ 5.0 million of aggregate principal amount was outstanding under the New Revolving Credit Facility, $ 76.0 million aggregate principal amount was outstanding under the New Term Loan Facility and $ 1.0 million of associated unamortized debt costs. As of June 30, 2021, $ 20.0 million of aggregate principal amount was outstanding under the New Revolving Credit Facility, $ 80 million aggregate principal amount was outstanding under the New Term Loan Facility and $ 1.3 million of associated unamortized debt costs. The following table presents the carrying value of the New Credit Facilities and the Notes as of June 30, 2022 (in thousands): Revolving 3.75% 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 2,865 $ 100,000 $ 76,000 $ 183,865 Unamortized debt costs — ( 1 ) ( 2,381 ) ( 1,013 ) ( 3,395 ) Unamortized debt discount — — — — — Net carrying amount $ 5,000 $ 2,864 $ 97,619 $ 74,987 $ 180,470 Reported as: Short-term debt $ 8,563 Long-term debt 171,907 Total debt $ 180,470 A summary of interest expense on the New Credit Facilities and the Notes is as follows (in thousands): Year ended June 30, 2022 2021 2020 Interest expense related to contractual interest coupon $ 7,233 $ 10,590 $ 12,373 Interest expense related to amortization of debt discount — 4,887 4,168 Interest expense related to amortization of debt issuance costs 909 1,356 1,350 Interest expense related to extinguishment of debt — 9,948 — Total $ 8,142 $ 26,781 $ 17,891

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Note 11. Shareholders’ Equity At June 30, 2022, the Company had 1.6 million s hares of common stock reserved for issuance under the stock incentive plans and the employee stock purchase plan. Share Repurchase On May 5, 2021, the Board of Directors authorized a repurchase of an aggregate amount of the Company common stock not to exceed $ 18 million. On May 7, 2021, the Company completed a repurchase of 3,108,369 shares of its common stock for an aggregate amount of $ 14.1 million. The Company’s common stock is reduced by an amount equal to the number of shares being repurchased multiplied by the par value of such shares. The excess amount that is repurchased over its par value is first allocated as a reduction to additional paid-in capital based on the initial public offering price of the Company’s common stock.

Stock Incentive Plan and Employ

Stock Incentive Plan and Employee Stock Purchase Plan	12 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Stock Incentive Plan and Employee Stock Purchase Plan	Note 12. Stock Incentive Plan and Employee Stock Purchase Plan As of June 30, 2022 , the Company had two outstanding stock incentive plans: the 2016 Equity Incentive Plan, or the 2016 Plan and the 2007 Incentive Award Plan, or the 2007 Plan. The 2016 Plan permits the granting of stock options, stock appreciation rights, restricted stock awards, performance shares, performance units, and restricted stock units, or RSUs. The vesting of RSUs granted under the 2016 Plan are primarily service‑based (over the requisite service period) while the vesting of performance units granted under the 2016 Plan are primarily performance‑based, or PSUs, or market‑based, or MSUs. Only employees of the Company are eligible to receive incentive stock options. Non‑employees may be granted non‑qualified stock options. Stock options granted under the 2016 Plan have an exercise price of at least 100 % of the fair market value of the underlying stock on the grant date. The stock options have 10 year contractual terms and generally become exercisable for 25 % of the option shares one year from the date of grant and then ratably over the following 36 months. Service‑based RSUs granted under the equity plans generally vest 25 % of the share units covered by the grant on each of the first through fourth anniversaries of the date of the grant, subject to the continued service of the grantee through each such date. However, certain of the outstanding RSUs under our equity plans vest 50 % upon the first anniversary year of the grant date, and 50 % upon the second anniversary year of the grant date. The Board of Directors has the discretion to use different vesting schedules. As of June 30, 2022, the 2007 Plan continued to remain in effect; however, the Company can no longer grant equity awards under such plans. The following table summarizes the share‑based compensation charges included in the Company’s consolidated statements of operations and comprehensive income (loss) (in thousands): Years ended June 30, 2022 2021 2020 Cost of revenue $ 1,584 $ 1,296 $ 1,244 Research and development 1,371 1,348 1,457 Selling and marketing 2,213 1,457 1,159 General and administrative 5,432 5,231 4,292 Total $ 10,600 $ 9,332 $ 8,152 The amount of capitalized share‑based compensation costs as components of inventory was insignificant at June 30, 2022, 2021 and 2020. Stock Options The fair value of each option is estimated at the date of grant using the Black‑Scholes option pricing formula with the following assumptions: Years Ended June 30, 2022 2021 2020 Risk–free interest rate 2.71 % - 3.21 % 0.59 % - 1.27 % 1.14 % - 1.53 % Dividend yield — % — % — % Expected term 7.30 - 8.94 6.72 - 6.88 5.63 - 5.64 Expected volatility 54.1 % - 57.3 % 54.7 % - 55.6 % 47.3 % - 48.9 % Determining Fair Value of Stock Options The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Valuation and Amortization Method —The Company estimates the fair value of its stock options using the Black‑Scholes option‑pricing model. This fair value is then amortized over the requisite service periods of the awards. Expected Term —The Company estimates the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by the simplified method. Expected Volatility —The expected volatility is derived from the Company’s historical stock volatility over a period approximately equal to the expected term of the options. Risk‑Free Interest Rate —The risk‑free interest rate is based on the U.S. Treasury yield curve on the date of grant. Dividend Yield —The dividend yield assumption is based on the Company’s history and expectation of no dividend payouts. A summary of option activity under the Company’s incentive plan during the fiscal years is presented below (in thousands except per share and term amounts): Options Weighted Weighted Aggregate Balance at June 30, 2019 5,220 $ 4.50 7.97 $ 11 Options granted 2,305 2.64 Options exercised — — Options forfeited/expired ( 1,569 ) 4.36 Balance at June 30, 2020 5,956 3.82 8.04 $ — Options granted 1,526 4.48 Options exercised ( 209 ) 4.09 Options forfeited/expired ( 243 ) 4.40 Balance at June 30, 2021 7,030 3.93 7.66 $ 5,036 Options granted 756 2.05 Options exercised ( 331 ) 3.69 Options forfeited/expired ( 402 ) 4.05 Balance at June 30, 2022 7,053 3.73 7.05 $ — Vested or Expected to vest at June 30, 2022 7,053 3.73 7.05 Exercisable at June 30, 2022 4,576 $ 4.00 6.27 $ — The aggregate intrinsic value in the table above represents the total pre‑tax intrinsic value (the difference between the fair value of the Company’s common stock on June 30, 2022 of $ 1.96 and the exercise price of the options that would have been received by option holders if all options exercisable had been exercised on June 30, 2022). The total intrinsic value of options exercised in the years ended June 30, 2022, 2021 and 2020 was approximately $ 0.3 million, $ 0.2 million and $ 0 million, respectively. During the years ended June 30, 2022, 2021 and 2020 , the Company recognized $ 2.6 million, $ 2.4 million and $ 2.0 million, respectively, of share‑based compensation expense for stock options granted to employees. Tax benefits from tax deductions for exercised options and disqualifying dispositions in excess of the deferred tax asset attributable to stock compensation costs for such options are credited to additional paid‑in capital. The benefits are recognized against income taxes. Realized excess tax benefits related to stock options exercises was zero for each of the years ended June 30, 2022, 2021 and 2020. As of June 30, 2022, there was approximatel y $ 3.1 million of unrecognized compensation cost net of estimated forfeitures, related to unvested stock options, which is expected to be recognized over a weighted average period of 2.4 years. The following table summarizes information about outstanding and exercisable options at June 30, 2022 (in thousands, except years and exercise price): Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Weighted Number Weighted $ 1.96 – 2.08 756 9.94 $ 2.05 — $ — $ 2.60 – 2.60 1,533 7.34 2.60 1,022 2.60 $ 2.97 – 4.00 623 6.42 3.52 500 3.65 $ 4.10 – 4.10 2,048 6.42 4.10 1,835 4.10 $ 4.46 – 4.46 1,113 8.42 4.46 441 4.46 $ 4.52 – 6.96 980 4.51 5.36 778 5.44 Total Outstanding 7,053 7.05 3.73 4,576 $ 4.00 Restricted Stock The following table summarizes the activity of RSUs, PSUs and MSUs (in thousands, except fair value per share): Unvested Restricted Stock Restricted Performance Market Total Weighted Unvested at June 30, 2019 3,084 - 641 3,725 $ 4.34 Granted 2,009 419 — 2,428 2.74 Vested ( 1,579 ) — — ( 1,579 ) 4.62 Cancelled/Forfeited ( 343 ) — ( 470 ) ( 813 ) 3.96 Unvested at June 30, 2020 3,171 419 171 3,761 3.26 Granted 1,738 280 — 2,018 4.16 Vested ( 1,452 ) — — ( 1,452 ) 3.52 Cancelled/Forfeited ( 539 ) ( 419 ) ( 171 ) ( 1,129 ) 3.20 Unvested at June 30, 2021 2,918 280 — 3,198 3.73 Granted 3,236 937 — 4,173 3.75 Vested ( 1,341 ) — — ( 1,341 ) 3.75 Cancelled/Forfeited ( 252 ) ( 642 ) — ( 894 ) 3.87 Unvested at June 30, 2022 4,561 575 — 5,136 $ 3.74 As of June 30, 2022, there was approximately $ 11.0 million of unrecognized compensation cost, net of estimated forfeitures, related to restricted stock, which is expected to be recognized over a weighted average period of 2.2 years. Restricted Stock Units The Company recognized $ 6.7 million, $ 5.4 million and $ 4.9 million of share‑based compensation expense, net of estimated forfeitures, related to RSUs during the years ended June 30, 2022, 2021 and 2020 . The weighted average grant date fair value per share of RSUs granted was $ 3.75 , $ 4.16 and $ 2.74 for the years ended June 30, 2022, 2021 and 2020, respectively. The aggregate fair market value of RSUs that vested during the year ended June 30, 2022 was $ 6.4 million. Performance Stock Units The Compensation Committee approved the grant of 937,000 , 280,000 and 419,000 PSUs to select employees of the Company in the years ended June 30, 2022, 2021 and 2020, respectively. No PSUs vested in the years ended June 30, 2022 and June 30, 2021. During the years ended June 30, 2022, 2021 and 2020, 642,000 , 419,000 and zero PSUs were cancelled, respectively. The Company recognized zero share‑based compensation expense, net of estimated forfeitures, related to PSUs during the years ended June 30, 2022, 2021, and 2020. Market Stock Units The Compensation Committee approved the performance equity program, referred to as the Market Stock Unit (MSU) program, or MSU program, in October 2012. The Company’s MSU Program uses the Russell 2000 index as a performance benchmark and requires that the Company’s total stockholder return match or exceed that of the Russell 2000. Based on a sliding scale of how much the Company’s total stockholder return outperforms the Russell 2000 benchmark, the participating executives can earn up to a maximum of 150 % of the target number of shares over two measurement periods. The Company uses a Monte Carlo simulation to calculate the fair value of the award on the grant date. The Compensation Committee approved no grants of MSUs in the years ended June 30, 2022 and 2021 . Of these MSUs, no shares vested in the years ending June 30, 2022, 2021 and 2020 , respectively, due to the non-achievement of the requisite performance target against the Russell 2000 index while zero , 0.2 million and 0.5 million MSUs were cancelled in the years ended June 30, 2022, 2021 and 2020, respectively. The Company recognized zero , $ 0.1 million and $ 0.2 million of share‑based compensation expense, net of estimated forfeitures, related to MSUs during the years ended June 30, 2022, 2021 and 2020, respectively. There were no MSUs granted during the years ended June 30, 2022, 2020 and 2019. As of June 30, 2022 , there was no unrecognized compensation cost related to MSUs. Employee Stock Purchase Plan Under the Company’s Amended and Restated 2007 Employee Stock Purchase Plan, or ESPP, qualified employees are permitted to purchase the Company’s common stock at 85 % of the lower of the fair market value of the common stock on the commencement date of each offering period or the fair market value on the specified purchase date. Employees’ payroll deductions may not exceed 10 % of their salaries. Employees may purchase up to 2,500 shares per period provided that the value of the shares purchased in any calendar year may not exceed $ 25,000 , as calculated pursuant to the purchase plan. The Company estimates the fair value of ESPP shares at the date of grant using the Black‑Scholes option pricing model. The weighted average assumptions were as follows: Years Ended June 30, 2022 2021 2020 Risk–free interest rate 0.10 % - 2.16 % 0.04 % - 0.10 % 0.17 % - 1.60 % Dividend yield —% —% —% Expected term 0.5 - 1.0 0.5 - 1.0 0.5 - 1.0 Expected volatility 35.49 % - 54.33 % 36.10 % - 65.58 % 45.46 % - 75.21 % The risk‑free rate for the expected term of the ESPP option was based on the U.S. Treasury Constant Maturity rate for each offering period; expected volatility was based on the historical volatility of the Company’s common stock; and the expected term was based upon the offering period of the ESPP. For the years ended June 30, 2022, 2021 and 2020, the Company recognized $ 1.3 million, $ 1.4 million and $ 1.1 million, respectively, of compensation expense related to its ESPP. The Company issued 1.1 million, 1.2 million and 1.1 million shares under the ESPP during fiscal 2022, 2021 and 2019, respectively, at a weighted average price per share o f $ 4.33 , $ 1.90 and $ 2.16 , respectively. As of June 30, 2022, total unrecognized compensation cost related to the ESPP plan was $ 0.4 million , which the Company expects to recognize over a weighted average per iod of 0.6 years.

Joint Venture

Joint Venture	12 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture	Note 13. Joint Venture In January 2019, the Company’s wholly-owned subsidiary, Accuray Asia Limited (“Accuray Asia”), entered into an agreement with CNNC High Energy Equipment (Tianjin) Co., Ltd. (the “CIRC Subsidiary”), a wholly-owned subsidiary of China Isotope & Radiation Corporation, to form a joint venture, CNNC Accuray (Tianjin) Medical Technology Co. Ltd. (the “JV”), to manufacture and sell radiation oncology systems in China. In exchange for the 49 % equity interest in the JV, the Company, through Accuray Asia, made in-kind capital contributions of two full radiation oncology systems in the quarter ended December 31, 2019 and one system upgrade in the quarter ended September 30, 2020, all of which was not to be sold and only be used for training purposes by the JV. The investments are reported as an Investment in joint venture on the Company’s consolidated balance sheets. The Company applies the equity method of accounting to its ownership interest in the JV as the Company has the ability to exercise significant influence over the JV but lacks controlling financial interest and is not the primary beneficiary. The Company recognizes the 49 % proportionate share of the JV income or loss on a one-quarter lag due to the timing of the availability of the JV’s financial records. The Company recognizes revenue on sales to the JV in the current period of control transfer, eliminating a portion of profit to the extent goods sold have not been sold through by the JV to an end customer by the end of each reporting period. During the years ended June 30, 2022 and 2021, respectively, the Company recognized $ 1.4 million and $ 1.8 million of previously deferred intra-entity profit margin from sales and recorded intra-entity profit margin deferrals of $ 4.7 million and $ 2.1 million fro m sales recognized during the period. The Company’s consolidated accumulated deficit at June 30, 2022 includes $ 1.0 million of cumulative income related to the Company’s equity method investment. As of June 30, 2022, the Company had a carrying value of $ 13.9 million in the JV and owned a 49 % interest in the entity. The Company’s proportional share of the underlying equity in net assets of the JV was approximately $ 14.6 million. Under the equity method of accounting, the carrying value of the investment is adjusted for the Company's proportional share of the investee's currency translation adjustment of $ 1.0 million. The difference between the carrying value of the equity investment and the Company’s proportional share of the underlying equity in net assets of the JV of $ 1.7 million adding back $ 5.4 million of eliminated intra-entity profit constitutes equity method goodwill of $ 4.7 million at June 30, 2022 that is subject to impairment analysis. No i mpairment was identified as of June 30, 2022. Summarized financial information of the JV is as follows (in thousands): Statement of Operations Data: Twelve Months Ended Twelve Months Ended Revenue $ 55,190 $ 33,054 Gross Profit $ 15,915 $ 10,578 Net income $ 422 $ 1,785 Net income attributable to the Company $ 241 $ 872 Summarized Balance Sheet Data: As of As of Assets Current assets $ 71,730 $ 24,703 Non current assets 21,754 23,089 $ 93,484 $ 47,792 Liabilities and Stockholders' Equity Current liabilities $ 61,877 $ 16,854 Non current liabilities 1,055 1,467 Stockholder's equity 30,552 29,471 $ 93,484 $ 47,792

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 14. Income Taxes Income (loss) before provision for income taxes on the accompanying statements of operations and comprehensive loss included the following components (in thousands): Years Ended June 30, 2022 2021 2020 Domestic $ ( 14,092 ) $ ( 8,448 ) $ ( 1,811 ) Foreign 12,090 3,889 7,501 Total worldwide $ ( 2,002 ) $ ( 4,559 ) $ 5,690 The provision for income taxes consisted of the following (in thousands): Years Ended June 30, 2022 2021 2020 Current: Federal $ — $ — $ — State 25 17 15 Foreign 1,535 1,849 1,495 Total current $ 1,560 $ 1,866 $ 1,510 Deferred: Federal — — — State — — — Foreign 1,785 ( 114 ) 353 Total deferred 1,785 ( 114 ) 353 Total provision for income taxes $ 3,345 $ 1,752 $ 1,863 A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands): Years Ended June 30, 2022 2021 2020 U.S. federal taxes (benefit): At federal statutory rate $ ( 420 ) $ ( 958 ) $ 1,195 State tax, net of federal benefit 25 17 15 Share-based compensation expense 592 879 810 Debt extinguishment — 898 — Other non-deductible permanent items 252 155 418 R&D credits ( 415 ) ( 1,278 ) ( 635 ) Foreign taxes ( 948 ) 918 273 Other ( 97 ) ( 57 ) ( 69 ) Deferred Tax on foreign earnings 1,730 — — Global Intangible Low-Taxed Income 2,124 243 1,185 Change in valuation allowance 502 935 ( 1,329 ) Total $ 3,345 $ 1,752 $ 1,863 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets (liabilities) were as follows (in thousands): June 30, 2022 2021 Deferred tax assets: Federal and state net operating losses $ 75,450 $ 75,033 Accrued expenses and reserves 7,359 6,597 Lease liability 3,037 4,258 Deferred revenue 5,505 5,093 R&D Credits 25,146 24,340 Share-based compensation expense 1,406 1,096 Capitalized research and development 1,440 2,088 Unicap 489 1,827 Fixed assets/intangibles 956 1,055 Section 163(j) interest 2,350 1,817 Other 228 1,082 Total deferred tax assets 123,366 124,286 Deferred tax liabilities: Contract acquisition costs ( 1,521 ) ( 1,174 ) Right of use assets ( 2,517 ) ( 3,533 ) Debt — ( 5,612 ) Deferred tax on foreign earnings ( 1,730 ) — Total deferred tax liabilities ( 5,768 ) ( 10,319 ) Valuation allowance ( 119,115 ) ( 113,476 ) Net deferred tax assets (liabilities) $ ( 1,517 ) $ 491 As of June 30, 2022, the Company h ad approximately $ 324.0 million and $ 131.1 million in federal and state net operating loss carryforwards, respectively. The federal and state carryforwards expire in varying amounts beginning in 2025 for federal and 2023 for state purposes. In addition, as of June 30, 2022 , the Company had federal and state research and development tax credits of approximately $ 25.5 million and $ 22.1 million, respectively. If not utilized, the federal research credits will begin to expire in 2023, the California research credits have no expiration date and the other state research credits will begin to expire in 2023. Under the Internal Revenue Code ("IRC") Sections 382 and 383, annual use of our net operating loss and research tax credit carryforwards to offset taxable income may be limited based on cumulative changes in ownership. Although ownership changes have occurred in the prior years, the carryovers should be available for utilization by the Company before they expire, provided the Company generates sufficient future taxable income. During the current period, an analysis of the impact of this provision through March 31, 2022 has been performed and it was determined that no ownership change has occurred after December 2009. Based on the available objective evidence and history of losses, the Company has established a 100 % valuation allowance against its combined domestic net deferred tax assets because of uncertainty surrounding the realization of such deferred tax assets. Beginning fiscal year 2019, for U.S. federal tax purposes, certain income earned by controlled foreign corporations (“CFCs”) must be included currently in the gross income of the CFC’s U.S. shareholder. The income required to be included in gross income is referred to as global intangible low tax income (“GILTI”) and is defined under IRC Section 951A as the excess of the shareholder’s net CFC tested income over the net deemed tangible income return. The GILTI inclusion amount has been absorbed by net operating losses. The Company has made a policy decision to record GILTI tax as a current-period expense when incurred. The recorded income tax expense for fiscal year 2022 includes $ 1.7 million of Swiss withholding tax expected to be paid on the remittance of unrepatriated distributable reserves in France, Japan and Switzerland. At June 30, 2022, we have undistributed earnings of certain foreign subsidiaries of approximately $ 18.1 million that we have indefinitely invested, and on which we have not recognized deferred taxes. The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands): Years Ended June 30, 2022 2021 2020 Balance at beginning of year $ 18,765 $ 16,996 $ 16,280 Tax positions related to current year: Additions 1,222 1,433 954 Tax positions related to prior years: Additions 61 786 286 Reductions ( 238 ) ( 450 ) ( 524 ) Balance at end of year $ 19,810 $ 18,765 $ 16,996 The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company’s tax positions with respect to legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The reduction in prior year's tax positions primarily relates to lapses of applicable statutes of limitations. The Company anticipates there will be no material changes in uncertain tax positions in the next 12 months. As of June 30, 2022, the amount of gross unrecognized tax benefits was $ 19.8 million of which $ 19.6 million would not affect income tax expense before consideration of any valuation allowance. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of June 30, 2022 and 2021, the Company had approximately $ 0.06 million and $ 0.05 million, respectively, of cumulative accrued interest and penalties related to uncertain tax positions. The Company files income tax returns in the United States federal, various states, and foreign jurisdictions. Due to tax attributes being carried forward and utilized during open years, the statute of limitations remains open for the U.S. federal jurisdiction and domestic states for tax years from 2002 and forward. The statutes of limitation with respect to the foreign jurisdictions where the Company files income tax returns vary from jurisdiction to jurisdiction and range from 3 to 10 years and the material foreign jurisdictions are France, Switzerland and Japan. The Company is also subject to examination of its income tax returns by the Internal Revenue Service (IRS) and other foreign tax authorities, and in some cases the Company has received additional tax assessments which have not been significant. Currently, the Company is under the early stages of audit by the Japanese tax authorities for the fiscal periods 2019, 2020 and 2021.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Employee Benefit Plan	Note 15. Employee Benefit Plan The Company’s employee savings and retirement plan is qualified under Section 401(k) of the United States Internal Revenue Code. Employees may make voluntary, tax‑deferred contributions to the 401(k) Plan up to the statutorily prescribed annual limit. The Company makes discretionary matching contributions to the 401(k) Plan on behalf of employees up to the limit determined by the Board of Directors. The Company contributed $ 2.3 million, $ 1.1 million and $ 2.0 million to the 401(k) Plan during the years ended June 30, 2022, 2021 and 2020, respectively.

Defined Benefit Pension Obligat

Defined Benefit Pension Obligation	12 Months Ended
	Jun. 30, 2022
Defined Benefit Pension Obligation Disclosure [Abstract]
Defined Benefit Pension Obligation	Note 16. Defined Benefit Pension Obligation The Company has established a defined benefit pension plan for its employees in its Switzerland subsidiary. The plan provides benefits to employees upon retirement, death or disability. The Company uses June 30 as the year‑end measurement date for this plan. T he unfunded liability of $ 0.1 million was recognized in long‑term other liabilities in the accompanying balance sheet as of June 30, 2022. Actuarial gain of $ 4.3 million was reco gnized in other comprehensive loss in fiscal 2022. Obligations and Funded Status The following table presents the funded status of the defined benefit pension plan (in thousands): June 30, 2022 2021 Change in benefit obligation: Benefit obligation—beginning of fiscal year $ 18,705 $ 18,426 Service cost 1,513 1,766 Interest cost 75 38 Plan participants’ contributions 2,554 1,676 Plan amendment ( 699 ) 25 Actuarial (gain)/loss ( 3,460 ) ( 807 ) Foreign currency changes ( 577 ) 281 Benefit and expense payments ( 658 ) ( 2,700 ) Benefit obligation—end of fiscal year $ 17,453 $ 18,705 Change in plan assets: Plan assets—beginning of fiscal year $ 14,419 $ 13,958 Employer contributions 1,225 1,117 Actual return on plan assets 374 199 Plan participants’ contributions 2,554 1,676 Foreign currency changes ( 564 ) 169 Benefit and expense payments ( 658 ) ( 2,700 ) Plan assets—end of fiscal year $ 17,350 $ 14,419 Funded status $ ( 103 ) $ ( 4,286 ) Amounts recognized within the consolidated balance sheets: Assets $ — $ — Long-term other liabilities ( 103 ) ( 4,286 ) Net amount recognized $ ( 103 ) $ ( 4,286 ) The following table presents the amounts recognized in accumulated other comprehensive loss (before tax) for the defined benefit pension plan (in thousands): June 30, 2022 2021 Net actuarial loss (gain) $ 3,723 $ ( 1,236 ) Prior service cost 224 872 Accumulated other comprehensive income (loss) $ 3,947 $ ( 364 ) The following table presents the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for this defined benefit pension plan where accumulated benefit obligation exceeded the fair value of plan assets (in thousands): June 30, 2022 2021 Projected benefit obligation $ 17,453 $ 18,705 Accumulated benefit obligation $ 15,546 $ 16,891 Fair value of plan assets $ 17,350 $ 14,419 Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Loss The following table shows the components of the Company’s net periodic benefit costs and the other amounts recognized in other comprehensive loss, before tax, related to the Company’s defined benefit pension plan (in thousands): Year ended June 30, 2022 2021 2020 Net Periodic Benefit Costs: Service cost $ 1,513 $ 1,766 $ 2,003 Interest cost 75 38 62 Expected returns on assets ( 144 ) ( 142 ) ( 151 ) Amortization of prior service cost 54 54 ( 2 ) Amortization of net loss — — — Settlement charges — — 178 Net periodic benefit costs 1,498 1,716 2,090 Other Amounts Recognized in Other Comprehensive Loss: Net (gain) loss arising during the year ( 3,584 ) ( 850 ) ( 593 ) Prior service cost ( 53 ) ( 54 ) 2 Amortization of prior service cost ( 678 ) 24 1,005 Amortization of net gain — — — Effect of settlement 4 8 ( 178 ) Total recognized in other comprehensive (gain) loss ( 4,311 ) ( 872 ) 236 Total recognized in net periodic benefit costs and other $ ( 2,813 ) $ 844 $ 2,326 The amounts in accumulated other comprehensive loss that are expected to be recognized as components of net periodic benefit cost during fiscal year 2023 related to the Company’s defined benefit pension plan are as follows (in thousands): 2023 Net gain $ 172 Prior service credit 24 Accumulated other comprehensive income $ 196 Assumptions The assumptions used to determine net periodic benefit cost and to compute the expected long‑term return on assets for the Company’s defined benefit pension plan were as follows: Fiscal Years 2022 2021 2020 Net Periodic Benefit Costs: Discount rate 1.90 % 0.40 % 0.25 % Rate of compensation increase 1.75 % 1.50 % 1.50 % Expected long-term return on assets 1.00 % 1.00 % 1.00 % The assumptions used to measure the benefit obligation for the Company’s defined benefit pension plan were as follows: June 30, 2022 2021 Benefit Obligation: Discount rate 1.90 % 0.40 % Rate of compensation increase 1.75 % 1.50 % Estimated Contributions and Future Benefit Payments The Company made contributions of approxima tely $ 1.2 million, $ 1.1 million and $ 1.3 million to the defined benefit pension plan during fiscal years 2022, 2021 and 2020 respectively. The Company expects total contributions to the defined benefit pension plan for fiscal year 2023 will be approximately $ 1.3 million. Estimated future benefit payments expected to be paid by the defined benefit pension plan at June 30, 2022 are as follows (in thousands): Year Ending June 30, Future 2023 $ 1,001 2024 1,015 2025 1,212 2026 1,054 2027 1,218 Thereafter 8,605 Total $ 14,105 Plan Assets The plan assets are invested in insurance contracts with Copré Collective Foundation based in Lausanne, Switzerland at the end of fiscal years 2022 and 2021, respectively. In fiscal 2022 and 2021, the risks of death and disability are reinsured with Zurich Life Insurance. The Copré Foundation for Occupational Benefits defines and is responsible for the asset strategy and invests the plan assets for the Company. In fiscal 2022 and 2021 the guaranteed interest rate for mandatory retirement savings was 1.00 % for both years . The technical administration and management of the savings account are guaranteed by the Copré Foundation for Occupational Benefits. Insurance benefits due are paid directly to the entitled persons by the Copré Foundation for Occupational Benefits. Accuray International Sàrl has committed itself to pay the annual contributions and costs due under the pension fund regulations. The contract of affiliation between the Company and the Copré Collective Foundation can be terminated by either side. In the event of a termination, recipients of retirement and survivors’ benefits would remain with the collective foundation. The Company commits itself to transfer its active insured members and recipients of disability benefits to the new employee benefits institution, thus releasing the Copré Collective Foundation from all obligations.

Segment Disclosure

Segment Disclosure	12 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Disclosure	Note 17. Segment Disclosure The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics. Therefore, the information below is presented only for revenues and long‑lived tangible assets by geographic areas. Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Years ended June 30, 2022 2021 2020 Americas $ 126,005 $ 105,878 $ 128,562 Europe, Middle East, India and Africa 134,640 121,568 119,989 Asia Pacific, excluding Japan and China 28,953 26,425 31,297 Japan 53,376 62,636 72,688 China 86,935 79,782 30,392 Total $ 429,909 $ 396,289 $ 382,928 Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands): June 30, June 30, Americas $ 11,251 $ 10,588 Europe, Middle East, India and Africa 228 265 Asia Pacific, excluding Japan and China 272 170 Japan 265 701 China 669 608 Total $ 12,685 $ 12,332

Restructuring Charges

Restructuring Charges	12 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring Charges	Note 18. Restructuring Charges The Company incurred no restructuring charges for the years ended June 30, 2 022 and 2021. On May 27, 2020, the Company informed affected employees of a cost saving initiative designed to reduce operating costs through the elimination of approximately 3 percent of its global workforce. These restructuring charges of $ 1.1 million were recorded in cost of goods sold and operating expenses in the consolidated statements of operations, of which $ 0.5 million was paid during fiscal 2020 and $ 0.6 million is accrued in the consolidated balance sheet as of June 30, 2020. The remainder was paid in fiscal year 2021.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 19. Subsequent Events The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

The Company and its Significa_2

The Company and its Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties as a result of a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, which causes coronavirus disease 2019 (“COVID-19”) and has resulted in a worldwide pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the effects of and response to the pandemic are rapidly evolving and new information is regularly coming to light, particularly as new COVID-19 variants emerge. The Company's customers are diverting resources to treat COVID-19 patients and deferring non-urgent and elective procedures. Some customers, which include hospitals, major academic medical centers, and other related entities, have incurred significant losses during the COVID-19 pandemic due to reduced patient volume. These impacts on the Company's customers may adversely affect their ability to meet their financial and other contractual obligations, including to the Company. Furthermore, global economic uncertainty, including labor shortages and disruptions in the global supply chain, related to the COVID-19 pandemic may result in an incremental adverse impact on revenue, net income (loss) and cash flow and may require significant additional expenditures or cost-cutting to mitigate such impacts. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. The Company’s financial results have also been affected by the COVID-19 pandemic in various ways. The COVID-19 pandemic is adversely impacting the pace at which the Company’s backlog converts to revenue. This is primarily the result of pandemic-related delays in the timing of deliveries and installations, which has adversely affected our revenue. The Company has experienced such delays in deliveries and installations since the third quarter of fiscal year 2020 and expects that such delays in will continue, which could have a negative impact on revenue. The Company has experienced disruptions in its sales cycle as well as delays in customer payments and service agreements. The Company has also received requests from a few customers to extend payment terms or temporarily suspend service and corresponding payment obligations. While the Company has only received a small number of requests thus far, there can be no guarantee that more customers will not ask for the same in the future. In addition, as the COVID-19 pandemic continues to impact the global supply chain, disruptions in parts of our supply chain have resulted in delays in the receipt of certain components for our products as well as increased pricing pressure for such parts. These ongoing supply chain challenges and heightened logistics costs have adversely affected the Company's gross margins and net income (loss), and the Company’s current expectations are that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistic expenses through at least the remainder of the calendar year of 2022, if not longer. Furthermore, certain parts required for the manufacture and servicing of the Company's products, such as electronic components, are scarce and becoming increasingly difficult to source even at increased prices. If such parts become unavailable to the Company, it would not be able to manufacture or service our products, which would adversely impact revenue, gross margins, and net income (loss). As a result, the Company is carefully monitoring the pandemic and the potential length and depth of the resulting economic impact on our financial condition and results of operations. There remain uncertainties around the spread, severity and potential resurgence of COVID-19, the impact of new COVID-19 variants, vaccination deployment efforts, and how long the pandemic and associated health measures will last, the related financial impact cannot be reasonably estimated at this time, although the impacts are expected to continue and may significantly affect the Company’s business. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. However, the Company is unable to predict with certainty the impact of the COVID-19 pandemic, including its effect on global supply chain and logistics, will have on its ability to maintain compliance with the debt covenants contained in the credit agreement related to its Credit Facilities (as such terms are defined in Note 10 below), including financial covenants regarding the consolidated fixed charge coverage ratio and consolidated senior net leverage ratio. The Company was in compliance with such covenants at June 30, 2022. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be accelerated and become immediately payable. This may require the Company to obtain waivers or amendments to the credit agreement in order to maintain compliance and there can be no certainty that any such waiver or amendment will be available, or what the cost of such waiver or amendment, if obtained, would be. If the Company is unable to obtain necessary waivers or amendment and the debt under such credit facility is accelerated, the Company would be required to obtain replacement financing at prevailing market rates, which may not be favorable to the Company. There is no guarantee that the Company would be able to satisfy its obligations if any of its indebtedness is accelerated .
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic. Key estimates and assumptions made by the Company relate to revenue recognition and the assessment of stand-alone selling price (“SSP”), assessment of recoverability of goodwill, valuation of the Company's equity method investment in the JV, valuation of inventories, annual performance related bonuses, allowance for credit losses and loss contingencies. Actual results could differ materially from those estimates.
Foreign Currency	Foreign Currency The Company’s international subsidiaries use their local currencies as their functional currencies. For those subsidiaries, assets and liabilities are translated at exchange rates in effect at the balance sheet date and income and expense accounts at the average exchange rate. Resulting translation adjustments are excluded from the determination of net income (loss) and are recorded in accumulated other comprehensive loss as a separate component of stockholders’ equity. Net foreign currency exchange transaction gains or losses are included as a component of other expense, net, in the Company’s consolidated statements of operations and comprehensive income (loss).
Fair Value Measurements	Fair Value Measurements The carrying values of the Company’s financial instruments including cash equivalents, restricted cash, accounts receivable and accounts payable are approximately equal to their respective fair values due to the relatively short‑term nature of these instruments. Also refer to Note 8, Fair Value Measurements, for further details.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States and internationally.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties The Company’s cash and cash equivalents are mainly deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances. The Company ha d one customer t hat represented 10 % or more of total net revenue for the year ended June 30, 2022 and one and no customer that represented 10 % or more of total net revenue for the years ended June 30, 2021 and 2020, respectively. The Company had two customers as of June 30, 2022 and two customers as of June 30, 2021, respectively that each accounted for more than 10 % of accounts receivable, net. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for credit losses once collection efforts are unsuccessful. Historically, such losses have been within management’s expectations. Single‑source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required.
Restricted Cash	Restricted Cash Restricted cash primarily consists of cash that is temporarily held in bank accounts which are under the control of the lender to the New Credit Facility, certificates of deposit held as guarantees in connection with customer contracts and corporate leases as well as funds held as guarantees for Value‑Added Tax (VAT) obligations in a foreign jurisdiction.
Inventories	Inventories Inventories are stated at the lower of cost (on a first‑in, first‑out basis) or net realizable value. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management.
Revenue Recognition	Revenue Recognition The Company’s revenue consists of product revenue resulting from the sale of systems, system upgrades and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer, net of any discounts and taxes collected from customers that are remitted to government authorities. The Company’s revenue is primarily derived from sales of CyberKnife and TomoTherapy platforms and services, which include post-contract customer support (“PCS”), installation services, training and other professional services. The majority of the Company's revenue arrangements consist of multiple performance obligations, which can include system, upgrades, installation, training, services, construction, and consumables. For bundled arrangements, the Company accounts for individual products and services separately if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s products are generally sold without a right of return, and the Company’s contracts generally provide a fixed transaction price. The Company may offer incentives in the form of discounts, including volume system discounts, which are included in the contract and used to calculate the final fixed price of the arrangement. These discounts may pertain to all performance obligations in a specific contract or may be allocated to a specific performance obligation. The Company reviews payment terms extending beyond one year. If it is determined that a material financing component exists, we recognized as interest income over time. The Company applies the practical expedient to not adjust for a significant financing component if the gap between payment and delivery was expected, at the contract inception, to be less than one year. The Company offers customers the opportunity to trade in their older systems for a discount off the purchase of a new system. The Company generally does not provide specific trade-in prices or upgrade rights at the time of purchase of the original system. Trade-in or upgrade transactions are based on the then fair value of the system and are separately negotiated taking into consideration circumstances existing at the time of the trade-in or upgrade. Accordingly, implied trade-ins and upgrades discounts are not considered separate performance obligations in system sales agreements. When systems are traded in, historically, the Company was able to recondition (re-new) the traded-in systems and resell them. In such transactions, the Company would estimate the stand-alone selling price of the traded-in system and include such amount as additional transaction price in the new bundled system sale. During fiscal year 2020, however, demand for reconditioned systems decreased, and no fair value has been assigned to any of the systems that were traded-in during fiscal year 2021 and 2022. These trade-in systems may be used for spare parts harvesting in certain cases. Such spare parts generally require reconditioning. The SSP of performance obligations is determined based on observable prices at which the Company separately sells the products and services. If the SSP is not directly observable, then the Company will estimate the SSP considering market conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The contract consideration allocation is based on the SSP at contract inception. The consideration (net of any discounts) is allocated among separate products and services in a bundle based on their relative SSPs. Contract modifications typically add additional goods or services or change pricing. For such modifications, the most recent SSP is used for reallocation to the remaining performance obligations. The Company recognizes revenue for certain performance obligations at the point in time when control is transferred, such as delivery of products and upgrades. Service revenue is recognized over the term of the service period as the customer benefits from the services throughout the service period. Revenue related to services that are not part of a service contract and performed on a time-and-materials basis are recognized when performed. Service contracts recognized over time comprise a single stand-ready performance obligation satisfied over time as our customers simultaneously receive and consume benefits from the Company's performance. This performance obligation constitutes a series of services that are substantially the same and provided over time using the same measure of progress. Revenues derived from these arrangements are recognized over time using an output method based upon the passage of time as this provides a faithful depiction of the pattern of transfer of control. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer when the Company expects to generate future economic benefits from the related revenue-generating contracts. The Company capitalizes incremental contract acquisition costs, and amortizes such costs over a five year period, the period which the Company expects to benefit, based on historical service renewal rates, and expectations of future customer renewals. Most of the Company’s contract costs are associated with its internal sales force compensation program and a portion of its employee bonus program. The Company capitalizes and amortizes the incremental costs of obtaining a contract, primarily related to certain bonuses and sales commissions. The capitalized bonuses and sales commissions are amortized over a period of five years commencing upon the initial transfer of control of the system to the customer. The pattern of amortization is commensurate with the pattern of transfer of control of the performance obligations to the customer. The amortization of these contract assets is included in cost of sales, research and development, sales and marketing, and general and administrative expenses based on department headcount allocations in the consolidated statements of operations. The Company elected to use the practical expedient and expense as incurred commissions related to service renewals and upgrades because the amortization period be one year or less. The Company invoices its customers based on the billing schedules in its sales arrangements. Payment terms vary from 30 to 90 days, or longer, from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms. Deferred revenue for periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to services being performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for any period presented.
Deferred Revenue	Deferred Revenue Deferred revenue primarily consists of unfulfilled obligations from open contracts for which performance has already started including short-shipped items, deferred warranty, training, maintenance services and other unperformed or incomplete performance obligations. Service contracts outside of the warranty period, for maintenance services, in general, are considered month-to-month contracts. Deferred revenue includes deferred warranty expected to be recognized over the remaining warranty period for system already installed.
Customers Advances	Customer Advances Customer advances represent payments made by customers in advance of product shipment.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight‑line method over the estimated useful lives of the related assets. Leasehold improvements are depreciated on a straight‑line basis over the remaining term of the lease or the estimated useful life of the asset, whichever is shorter. Machinery and equipment are depreciated over five years . Furniture and fixtures are depreciated over four years . Computer and office equipment and computer software are depreciated over three years . Repairs and maintenance costs, which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred.
Software Capitalization Costs	Software Capitalization Costs Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.
Impairment of Long-Lived Assets	Impairment of Long‑Lived Assets The Company reviews long‑lived assets, including intangible assets, equity method investment in the JV, property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable using pretax undiscounted cash flows. Impairment, if any, is measured as the amount by which the carrying value of a long‑lived asset exceeds its fair value.
Goodwill	Goodwill Goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. The Company has assessed that it has one operating segment and one reporting unit, and the consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. The Company estimates the fair value of the reporting unit based on the Company’s closing stock price on the trading day closest to the annual review date multiplied by the outstanding shares on that date. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the estimated fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required. The Company adopted the new accounting guidance that simplifies the testing for goodwill impairment in the first quarter of fiscal 2019. There was no impairment of goodwill identified in the fiscal years ended June 30, 2022, 2021 and 2020 .
Shipping and Handling	Shipping and Handling The Company’s billings for shipping and handling for product shipments to customers are included in cost of products. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of products.
Advertising Expenses	Advertising Expenses The Company expenses the costs of advertising and promoting its products and services as incurred. Advertising expenses were approximatel y $ 0.2 million, $ 0.2 million and $ 0.2 million for the years ended June 30, 2022, 2021 and 2020 , respectively, and are included in selling and marketing expense in the consolidated statements of operations.
Research and Development Costs	Research and Development Costs Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct compensation, benefits, and other headcount related costs for research and development personnel; costs for materials used in research and development activities; costs for outside services and allocated portions of facilities and other corporate costs. The Company has entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research institutions worldwide. These agreements support the Company’s internal research and development capabilities.
Share-Based Compensation	Share‑Based Compensation The Company issues share‑based compensation awards to employees and directors in the form of stock options, restricted stock units (RSUs), performance units (PSUs), market stock units (MSUs) and employee stock purchase plan (ESPP) awards (collectively, awards). The exercise price of stock options granted is equal to the fair market value of the Company’s common stock on the date of grant. The Company measures and recognizes compensation expense for all stock‑based awards based on the awards’ fair value. Share‑based compensation for RSUs and PSUs is measured based on the value of the Company’s common stock on the grant date. The Company uses the Monte Carlo simulation model to estimate the grant date fair value of MSUs. Share‑based compensation for employee stock options and ESPP awards are measured on the date of grant using a Black‑Scholes option pricing model. Awards vest either on a vesting schedule or in a lump sum. The Company determines the fair value of each award as a single award and recognizes the expense on a straight‑line basis over the service period of the award, which is generally the vesting period. Stock options expire ten years from the date of grant. Share‑based compensation expense for stock options, RSUs, PSUs and the ESPP awards is based on awards ultimately expected to vest, and the expense is recorded net of estimated forfeitures. With respect to Performance Stock Units that are based on our corporate financial performance targets, or PSUs, the number of PSUs that will ultimately be awarded is contingent on the Company’s actual level of achievement compared to the corporate financial target performance targets. The Company recognizes expense for MSUs net of estimated forfeitures and does not adjust the expense for subsequent changes in the expected outcome of the market‑based vesting conditions.
Loss Contingencies	Loss Contingencies The Company is involved in various lawsuits, claims and proceedings that arise in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews these provisions quarterly and adjusts these provisions to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic and diluted net income (loss) per share is computed by dividing net income (loss) attributable to stockholders by the weighted average number of common shares outstanding during the year. Potentially dilutive outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share attributable to stockholders follows (in thousands): Years Ended June 30, 2022 2021 2020 Numerator: Net income (loss) used to compute basic and diluted loss $ ( 5,347 ) $ ( 6,311 ) $ 3,827 Denominator: Weighted average shares used to compute basic income (loss) 92,095 92,031 89,874 Weighted average shares used to compute diluted income (loss) 92,095 92,031 90,623 The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSU), Market Stock Units (MSU) and Performance Stock Units (PSU), and the purchase of shares under the Employee Stock Purchase Program (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net income (loss) per share when their effect would have been anti‑dilutive. Additionally, the outstanding 3.75 % Convertible Notes due July 2022 (the “ 3.75 % Convertible Notes due 2022”) and the 3.75 % Convertible Notes due June 2026 (the “ 3.75 % Convertible Notes due 2026” and together with the 3.75 % Convertible Notes due 2022, the “Notes”) are included in the calculation of diluted net income per share only if their inclusion is dilutive for periods during which the notes were outstanding. The following table sets forth all potentially dilutive securities excluded from the computation in the table above when their effect would have been anti‑dilutive (in thousands): As of June 30, 2022 2021 2020 Stock options 7,053 7,030 5,956 RSUs, PSUs and MSUs 5,775 3,198 3,761 12,828 10,228 9,717 Outstanding Convertible Notes—Diluted Share Impact Due to the optional cash settlement feature and management’s intent to settle the principal amount thereof in cash, the shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75 % Convertible Notes due 2022 and 3.75 % Convertible Notes due 2026 outstanding as of June 30, 2022, totaling approximately 0.5 million s hares and 17.1 million shares of the Company’s common stock, respectively, as of June 30, 2022, the effect of adding the shares were antidilutive and were not included in the basic and diluted net loss per common share table above. The shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75 % Convertible Notes due 2022 outstanding as of June 30, 2021 and 2020, totaled approximately 0.5 million and 14.9 million shares, respectively, of the Company’s common stock and the effect of adding the shares were antidilutive and were not included in the basic and diluted net income (loss) per common share table above.
Leases	Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statements of operations. The Company determines the lease term by agreement with lessor, including lease renewal and extension. As the leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
Equity Method Investment	Equity Method Investment In 2020, the Company adopted a new accounting policy related to equity method investments in connection with its equity investment in CNNC Accuray (Tianjin) Medical Technology Co. Ltd., the Company’s joint venture in China (the “JV”). The equity method investment that the Company holds in the JV for which the Company has the ability to exercise significant influence over the JV but lacks a controlling financial interest in the JV. The equity method investment is measured at cost and adjusted for impairment, if any, for the Company’s share of the JV's income or loss and intra-entity profits. The Company recognizes its proportionate share of income or loss from the JV on a one-quarter lag due to the timing of the availability of the JV’s financial records. Profit earned by the Company from the JV is eliminated through cost of goods sold until it is realized; such profits would generally be considered realized when the inventory has been sold through to third parties . Equity method goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. Our impairment analysis considers qualitative and quantitative factors that may have a significant impact on the JV's fair value. Qualitative factors include the investee's financial condition and business outlook, industry and sector performance, operational and financing cash flow activities, and other relevant factors affecting the JV. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments, which require judgment and the use of estimates, including discount rates, investee revenue and costs, and comparable market data, among others.
Income Taxes	Income Taxes The Company is required to estimate its income taxes in each of the tax jurisdictions in which it operates prior to the completion and filing of tax returns for such periods. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities. The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses, research and development credit carryforwards and other deferred tax assets. The Company records a valuation allowance to reduce its deferred tax assets to the amount the Company believes is more likely than not to be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its domestic and certain foreign net deferred tax assets. The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company’s tax positions in light of legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The Company anticipates there will be no material changes in uncertain tax positions in the next 12 months.
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) The components of comprehensive income (loss) consist of net income (loss), changes in foreign currency exchange rate translation and net changes related to a defined benefit pension plan. The changes in foreign currency exchange rate translation and net changes related to the defined benefit pension plan are excluded from earnings and reported as a component of stockholders’ equity. The foreign currency translation adjustment results from those subsidiaries not using the United States dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated at the current exchange rates at the end of each period, whereas revenues and expenses are translated at average exchange rates in effect during the period. The resulting cumulative translation adjustments are recorded directly to the accumulated other comprehensive loss account in stockholders’ equity.

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Pronouncement Recently Adopted
Accounting Pronouncements	Accounting Pronouncement Recently Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). Under ASU No. 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments when calculating diluted earnings per share. The Company adopted this standard effective July 1, 2021, using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The Company applied the provisions of this guidance to our 3.75 % convertible senior notes due June 2026 (“2026 Notes”). Upon adoption, the Company recorded an increase to Accumulated deficit of $ 0.8 million, a decrease to Additional paid-in capital of $ 25.6 million and an increase to Debt of $ 24.8 million. There was no impact to diluted loss per share as the inclusion of potential shares of common stock related to the 2026 Notes would have been anti-dilutive. For further information, see Note 10, Debt.
Accounting Pronouncements Not Yet Effective
Accounting Pronouncements	Accounting Pronouncements Not Yet Effective In March 2020, the FASB issued an update (ASU 2020-04) establishing Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company’s New Term Loan Facility and New Revolving Credit Facility applies Eurodollar rate LIBOR to the variable component of the interest rate, if a Benchmark transition event, or an early opt-in election, as applicable occurred a transition to the use of the Secured Overnight Financing Rate ("SOFR") to replace such rate. This accounting standard update was effective upon issuance and may be applied prospectively through December 31, 2022. The Company is currently evaluating the impact of the guidance and our options related to the practical expedients. In April 2021, the FASB issued ASU 2021-04, which included Topic 260 “Earnings Per Share”. This guidance clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. The ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2021-04 on its consolidated financial statements. In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendment addresses how to account for contract assets recognized under Topic 606 in a business combination. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact ASU 2021-08 will have on its financial statements.

The Company and its Significa_3

The Company and its Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share attributable to stockholders follows (in thousands): Years Ended June 30, 2022 2021 2020 Numerator: Net income (loss) used to compute basic and diluted loss $ ( 5,347 ) $ ( 6,311 ) $ 3,827 Denominator: Weighted average shares used to compute basic income (loss) 92,095 92,031 89,874 Weighted average shares used to compute diluted income (loss) 92,095 92,031 90,623
Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per common share	The following table sets forth all potentially dilutive securities excluded from the computation in the table above when their effect would have been anti‑dilutive (in thousands): As of June 30, 2022 2021 2020 Stock options 7,053 7,030 5,956 RSUs, PSUs and MSUs 5,775 3,198 3,761 12,828 10,228 9,717

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Contract with Customer, Asset and Liability	Changes in the contract assets and contract liabilities are as follows: June 30, June 30, Change (Dollars in thousands) Amount Amount $ % Assets: Unbilled accounts receivable – current (1) $ 13,325 $ 12,354 971 8 Interest receivable – current (2) 493 512 ( 19 ) ( 4 ) Long-term accounts receivable (3) 5,301 4,970 331 7 Interest receivable – non-current (3) 683 1,083 ( 400 ) ( 37 ) Liabilities: Customer advances 25,290 24,937 353 1 Deferred revenue – current 75,375 81,660 ( 6,285 ) ( 8 ) Deferred revenue – non-current 24,694 23,685 1,009 4 (1) Included in accounts receivable on consolidated balance sheets (2) Included in prepaid expenses and other current assets on consolidated balance sheets (3) Included in other assets on consolidated balance sheets
Schedule of Remaining Performance Obligations related to Warranty	The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post warranty services as of June 30, 2022 and the estimated revenue expected to be recognized (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products). The Company has elected the practical expedient to not disclose the unsatisfied performance obligations of contracts with an original expected duration of one year or less. Fiscal years of revenue recognition (Dollars in thousands) 2023 2024 2025 Thereafter Long-term warranty and service $ 30,741 $ 20,491 $ 9,071 $ 8,797

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Jun. 30, 2022
Supplemental Financial Information Disclosure [Abstract]
Schedule of accounts receivable, net	Accounts receivable, net consisted of the following (in thousands): June 30, June 30, Accounts receivable $ 82,117 $ 74,054 Unbilled fees and services 13,325 12,354 95,442 86,408 Less: Allowance for credit losses ( 1,000 ) ( 1,048 ) Accounts receivable, net $ 94,442 $ 85,360
Schedule of financing receivables	A summary of the Company’s financing receivables is presented as follows (in thousands): June 30, 2022 June 30, 2021 Financing receivable $ 6,137 $ 7,102 Allowance for credit losses ( 943 ) ( 943 ) Total, net $ 5,194 $ 6,159 Reported as: Current $ 2,435 $ 2,772 Non-current 2,759 3,387 Total, net $ 5,194 $ 6,159
Schedule of inventories	Inventories consisted of the following (in thousands): June 30, June 30, Raw materials $ 61,871 $ 45,301 Work-in-process 16,367 22,014 Finished goods 64,016 58,614 Inventories $ 142,254 $ 125,929
Schedule of property and equipment, net	Property and equipment consisted of the following (in thousands): June 30, June 30, Furniture and fixtures $ 1,766 $ 1,636 Computer and office equipment 8,605 8,972 Software 5,344 7,477 Leasehold improvements 26,659 26,102 Machinery and equipment 46,522 45,265 Construction in progress 2,999 1,055 91,895 90,507 Less: Accumulated depreciation ( 79,210 ) ( 78,175 ) Property and equipment, net $ 12,685 $ 12,332
Schedule of components of accumulated other comprehensive income (loss)	The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands): Foreign Change in Total Balance at June 30, 2020 $ 752 $ ( 1,236 ) $ ( 484 ) Other comprehensive loss 1,705 872 2,577 Balance at June 30, 2021 $ 2,457 $ ( 364 ) $ 2,093 Other comprehensive loss ( 3,998 ) 4,311 313 Balance at June 30, 2022 $ ( 1,541 ) $ 3,947 $ 2,406
Schedule of consolidated statement of operations	Other expense, net consisted of the following (in thousands): Years Ended June 30, (in thousands) 2022 2021 2020 Interest expense $ ( 8,129 ) $ ( 16,893 ) ( 18,080 ) Foreign currency transaction loss ( 2,618 ) ( 1,953 ) ( 2,343 ) Gain on contribution to joint venture — — 12,964 Loss on Debt Extinguishment — ( 9,948 ) — Other expense, net 356 1,128 759 Total other expense, net $ ( 10,391 ) $ ( 27,666 ) $ ( 6,700 )

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligation	Operating lease right-of-use assets and operating lease obligation are represented in the table below (in thousands): June 30, June 30, Beginning balance operating lease right-of-use asset $ 22,522 $ 28,647 Lease asset added 3,522 1,069 Amortization for the year ( 9,246 ) ( 7,194 ) Ending balance operating lease right-of-use asset $ 16,798 $ 22,522 Beginning balance operating lease obligation $ 25,609 $ 32,397 Lease liability added 3,209 1,069 Repayment and interest accretion ( 9,798 ) ( 7,857 ) Ending balance operating lease obligation $ 19,020 $ 25,609 Current portion of operating lease obligation $ 8,567 $ 8,169 Noncurrent portion of operating lease obligation $ 10,453 $ 17,441
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of June 30, 2022 are presented in the table below (in thousands) : Year Ending June 30, Amount 2023 $ 9,554 2024 6,770 2025 3,631 2026 354 2027 197 Total operating lease payments 20,506 Less: imputed interest ( 1,486 ) Present value of operating lease liabilities $ 19,020

Goodwill and Purchased Intang_2

Goodwill and Purchased Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill and changes in the carrying amount of goodwill	Goodwill as of June 30, 2022 and 2021 and changes in the carrying amount of goodwill for the respective periods are as follows (in thousands): As of June 30, 2022 2021 Balance at the beginning of the period $ 57,960 $ 57,717 Currency translation adjustment ( 120 ) 243 Balance at the end of the period $ 57,840 $ 57,960
Schedule of intangible assets associated with purchased patent license	The Company’s intangible assets associated with purchased patent license are as follows (in thousands): As of June 30, 2022 As of June 30, 2021 Useful Gross Accumulated Net Gross Accumulated Net (in years) Patent license 2 - 7 $ 1,170 $ ( 920 ) $ 250 $ 1,170 $ ( 735 ) $ 435
Schedule of estimated future amortization expense of purchased intangible assets	The estimated future amortization expense of purchased intangible assets as of June 30, 2022 is as follows (in thousands): Year Ending June 30, Amount 2023 $ 143 2024 107 $ 250

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of outstanding forward currency exchange contracts	As of June 30, 2022 and 2021, the Company had the following outstanding forward currency exchange contracts (in notional amount): As of June 30, (In thousands and U.S. dollars) 2022 2021 Canadian Dollar $ — $ 527 Swiss Franc 27,910 8,891 Chinese Yuan 2,524 1,927 Euro 16,307 19,037 British Pound 3,699 3,191 Indian Rupee 3,728 7,825 Japanese Yen 14,167 12,803 $ 68,335 $ 54,201
Schedule of gain (loss) associated with the Company's derivative financial instruments	The following table provides information about gain (loss) associated with the Company’s derivative financial instruments (in thousands): Years ended June 30, 2022 2021 2020 Foreign currency exchange gain (loss) on forward contracts $ ( 2,045 ) $ ( 2,349 ) $ 744 Foreign currency transactions gain (loss) ( 887 ) 396 ( 3,087 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Summary of carrying values and estimated fair values of short-term and long-term debt	The following table summarizes the carrying value and estimated fair value of the Term Loan, the Revolving Credit Facility, the 3.75 % Convertible Notes due 2022 and the 3.75 % Convertible Notes due 2026 (in thousands): June 30, 2022 June 30, 2021 Carrying Fair Value Carrying Fair Value 3.75 % Convertible Notes Due 2022 $ 2,863 $ 2,729 $ 2,712 $ 3,164 3.75 % Convertible Notes Due 2026 97,619 78,561 72,388 108,163 Term Loan Facility 74,988 74,988 78,697 78,697 Revolving Credit Facility 5,000 5,000 20,000 20,000 Total $ 180,470 $ 161,278 $ 173,797 $ 210,024

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Long-term Principal and Interest on Notes and New Credit Facilities	Future minimum long‑term principal and interest on the Notes and New Credit Facilities (as defined below), including short-term portion, as of June 30, 2022 are as follows (in thousands): Year Ending June 30, Long-Term 2023 $ 16,266 2024 13,138 2025 14,827 2026 116,777 Total $ 161,008 (1) These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company’s consolidated balance sheet. Any conversion, premium, redemption or purchase of the Notes that would impact cash payments noted in the preceding table.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of carrying values of all Debt	The following table presents the carrying value of the New Credit Facilities and the Notes as of June 30, 2022 (in thousands): Revolving 3.75% 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 2,865 $ 100,000 $ 76,000 $ 183,865 Unamortized debt costs — ( 1 ) ( 2,381 ) ( 1,013 ) ( 3,395 ) Unamortized debt discount — — — — — Net carrying amount $ 5,000 $ 2,864 $ 97,619 $ 74,987 $ 180,470 Reported as: Short-term debt $ 8,563 Long-term debt 171,907 Total debt $ 180,470
Summary of interest expense on New Credit Facilities and Convertible Notes	A summary of interest expense on the New Credit Facilities and the Notes is as follows (in thousands): Year ended June 30, 2022 2021 2020 Interest expense related to contractual interest coupon $ 7,233 $ 10,590 $ 12,373 Interest expense related to amortization of debt discount — 4,887 4,168 Interest expense related to amortization of debt issuance costs 909 1,356 1,350 Interest expense related to extinguishment of debt — 9,948 — Total $ 8,142 $ 26,781 $ 17,891

Stock Incentive Plan and Empl_2

Stock Incentive Plan and Employee Stock Purchase Plan (Tables)	12 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Summary of share-based compensation charges included in the Company's consolidated statements of operations and comprehensive income (loss)	The following table summarizes the share‑based compensation charges included in the Company’s consolidated statements of operations and comprehensive income (loss) (in thousands): Years ended June 30, 2022 2021 2020 Cost of revenue $ 1,584 $ 1,296 $ 1,244 Research and development 1,371 1,348 1,457 Selling and marketing 2,213 1,457 1,159 General and administrative 5,432 5,231 4,292 Total $ 10,600 $ 9,332 $ 8,152
Schedule of assumptions used for determining fair value of stock options	The fair value of each option is estimated at the date of grant using the Black‑Scholes option pricing formula with the following assumptions: Years Ended June 30, 2022 2021 2020 Risk–free interest rate 2.71 % - 3.21 % 0.59 % - 1.27 % 1.14 % - 1.53 % Dividend yield — % — % — % Expected term 7.30 - 8.94 6.72 - 6.88 5.63 - 5.64 Expected volatility 54.1 % - 57.3 % 54.7 % - 55.6 % 47.3 % - 48.9 %
Schedule of option activity under the Company's Incentive Plan	A summary of option activity under the Company’s incentive plan during the fiscal years is presented below (in thousands except per share and term amounts): Options Weighted Weighted Aggregate Balance at June 30, 2019 5,220 $ 4.50 7.97 $ 11 Options granted 2,305 2.64 Options exercised — — Options forfeited/expired ( 1,569 ) 4.36 Balance at June 30, 2020 5,956 3.82 8.04 $ — Options granted 1,526 4.48 Options exercised ( 209 ) 4.09 Options forfeited/expired ( 243 ) 4.40 Balance at June 30, 2021 7,030 3.93 7.66 $ 5,036 Options granted 756 2.05 Options exercised ( 331 ) 3.69 Options forfeited/expired ( 402 ) 4.05 Balance at June 30, 2022 7,053 3.73 7.05 $ — Vested or Expected to vest at June 30, 2022 7,053 3.73 7.05 Exercisable at June 30, 2022 4,576 $ 4.00 6.27 $ —
Summary of information about outstanding and exercisable options	The following table summarizes information about outstanding and exercisable options at June 30, 2022 (in thousands, except years and exercise price): Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Weighted Number Weighted $ 1.96 – 2.08 756 9.94 $ 2.05 — $ — $ 2.60 – 2.60 1,533 7.34 2.60 1,022 2.60 $ 2.97 – 4.00 623 6.42 3.52 500 3.65 $ 4.10 – 4.10 2,048 6.42 4.10 1,835 4.10 $ 4.46 – 4.46 1,113 8.42 4.46 441 4.46 $ 4.52 – 6.96 980 4.51 5.36 778 5.44 Total Outstanding 7,053 7.05 3.73 4,576 $ 4.00
Summary of activity of RSUs, PSUs and MSUs	The following table summarizes the activity of RSUs, PSUs and MSUs (in thousands, except fair value per share): Unvested Restricted Stock Restricted Performance Market Total Weighted Unvested at June 30, 2019 3,084 - 641 3,725 $ 4.34 Granted 2,009 419 — 2,428 2.74 Vested ( 1,579 ) — — ( 1,579 ) 4.62 Cancelled/Forfeited ( 343 ) — ( 470 ) ( 813 ) 3.96 Unvested at June 30, 2020 3,171 419 171 3,761 3.26 Granted 1,738 280 — 2,018 4.16 Vested ( 1,452 ) — — ( 1,452 ) 3.52 Cancelled/Forfeited ( 539 ) ( 419 ) ( 171 ) ( 1,129 ) 3.20 Unvested at June 30, 2021 2,918 280 — 3,198 3.73 Granted 3,236 937 — 4,173 3.75 Vested ( 1,341 ) — — ( 1,341 ) 3.75 Cancelled/Forfeited ( 252 ) ( 642 ) — ( 894 ) 3.87 Unvested at June 30, 2022 4,561 575 — 5,136 $ 3.74
Schedule of weighted average assumptions used for determining fair value of ESPP shares	The Company estimates the fair value of ESPP shares at the date of grant using the Black‑Scholes option pricing model. The weighted average assumptions were as follows: Years Ended June 30, 2022 2021 2020 Risk–free interest rate 0.10 % - 2.16 % 0.04 % - 0.10 % 0.17 % - 1.60 % Dividend yield —% —% —% Expected term 0.5 - 1.0 0.5 - 1.0 0.5 - 1.0 Expected volatility 35.49 % - 54.33 % 36.10 % - 65.58 % 45.46 % - 75.21 %

Joint Venture (Tables)

Joint Venture (Tables)	12 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Summary of Financial Information of Joint Ventures (Operations Data)	Summarized financial information of the JV is as follows (in thousands): Statement of Operations Data: Twelve Months Ended Twelve Months Ended Revenue $ 55,190 $ 33,054 Gross Profit $ 15,915 $ 10,578 Net income $ 422 $ 1,785 Net income attributable to the Company $ 241 $ 872
Summary of Financial Information of Joint Ventures (Balance Sheet Data)	Summarized Balance Sheet Data: As of As of Assets Current assets $ 71,730 $ 24,703 Non current assets 21,754 23,089 $ 93,484 $ 47,792 Liabilities and Stockholders' Equity Current liabilities $ 61,877 $ 16,854 Non current liabilities 1,055 1,467 Stockholder's equity 30,552 29,471 $ 93,484 $ 47,792

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of components of income (loss) before provision for income taxes on the accompanying statements of operations and comprehensive loss	Income (loss) before provision for income taxes on the accompanying statements of operations and comprehensive loss included the following components (in thousands): Years Ended June 30, 2022 2021 2020 Domestic $ ( 14,092 ) $ ( 8,448 ) $ ( 1,811 ) Foreign 12,090 3,889 7,501 Total worldwide $ ( 2,002 ) $ ( 4,559 ) $ 5,690
Schedule of provision for income taxes	The provision for income taxes consisted of the following (in thousands): Years Ended June 30, 2022 2021 2020 Current: Federal $ — $ — $ — State 25 17 15 Foreign 1,535 1,849 1,495 Total current $ 1,560 $ 1,866 $ 1,510 Deferred: Federal — — — State — — — Foreign 1,785 ( 114 ) 353 Total deferred 1,785 ( 114 ) 353 Total provision for income taxes $ 3,345 $ 1,752 $ 1,863
Schedule of reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss	A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands): Years Ended June 30, 2022 2021 2020 U.S. federal taxes (benefit): At federal statutory rate $ ( 420 ) $ ( 958 ) $ 1,195 State tax, net of federal benefit 25 17 15 Share-based compensation expense 592 879 810 Debt extinguishment — 898 — Other non-deductible permanent items 252 155 418 R&D credits ( 415 ) ( 1,278 ) ( 635 ) Foreign taxes ( 948 ) 918 273 Other ( 97 ) ( 57 ) ( 69 ) Deferred Tax on foreign earnings 1,730 — — Global Intangible Low-Taxed Income 2,124 243 1,185 Change in valuation allowance 502 935 ( 1,329 ) Total $ 3,345 $ 1,752 $ 1,863
Schedule of significant components of net deferred tax assets (liabilities)	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets (liabilities) were as follows (in thousands): June 30, 2022 2021 Deferred tax assets: Federal and state net operating losses $ 75,450 $ 75,033 Accrued expenses and reserves 7,359 6,597 Lease liability 3,037 4,258 Deferred revenue 5,505 5,093 R&D Credits 25,146 24,340 Share-based compensation expense 1,406 1,096 Capitalized research and development 1,440 2,088 Unicap 489 1,827 Fixed assets/intangibles 956 1,055 Section 163(j) interest 2,350 1,817 Other 228 1,082 Total deferred tax assets 123,366 124,286 Deferred tax liabilities: Contract acquisition costs ( 1,521 ) ( 1,174 ) Right of use assets ( 2,517 ) ( 3,533 ) Debt — ( 5,612 ) Deferred tax on foreign earnings ( 1,730 ) — Total deferred tax liabilities ( 5,768 ) ( 10,319 ) Valuation allowance ( 119,115 ) ( 113,476 ) Net deferred tax assets (liabilities) $ ( 1,517 ) $ 491
Schedule of aggregate changes in the balance of gross unrecognized tax benefits	The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands): Years Ended June 30, 2022 2021 2020 Balance at beginning of year $ 18,765 $ 16,996 $ 16,280 Tax positions related to current year: Additions 1,222 1,433 954 Tax positions related to prior years: Additions 61 786 286 Reductions ( 238 ) ( 450 ) ( 524 ) Balance at end of year $ 19,810 $ 18,765 $ 16,996

Defined Benefit Pension Oblig_2

Defined Benefit Pension Obligation (Tables)	12 Months Ended
	Jun. 30, 2022
Defined Benefit Pension Obligation Disclosure [Abstract]
Schedule of funded status	The following table presents the funded status of the defined benefit pension plan (in thousands): June 30, 2022 2021 Change in benefit obligation: Benefit obligation—beginning of fiscal year $ 18,705 $ 18,426 Service cost 1,513 1,766 Interest cost 75 38 Plan participants’ contributions 2,554 1,676 Plan amendment ( 699 ) 25 Actuarial (gain)/loss ( 3,460 ) ( 807 ) Foreign currency changes ( 577 ) 281 Benefit and expense payments ( 658 ) ( 2,700 ) Benefit obligation—end of fiscal year $ 17,453 $ 18,705 Change in plan assets: Plan assets—beginning of fiscal year $ 14,419 $ 13,958 Employer contributions 1,225 1,117 Actual return on plan assets 374 199 Plan participants’ contributions 2,554 1,676 Foreign currency changes ( 564 ) 169 Benefit and expense payments ( 658 ) ( 2,700 ) Plan assets—end of fiscal year $ 17,350 $ 14,419 Funded status $ ( 103 ) $ ( 4,286 ) Amounts recognized within the consolidated balance sheets: Assets $ — $ — Long-term other liabilities ( 103 ) ( 4,286 ) Net amount recognized $ ( 103 ) $ ( 4,286 )
Schedule of amounts recognized in accumulated other comprehensive loss (before tax)	The following table presents the amounts recognized in accumulated other comprehensive loss (before tax) for the defined benefit pension plan (in thousands): June 30, 2022 2021 Net actuarial loss (gain) $ 3,723 $ ( 1,236 ) Prior service cost 224 872 Accumulated other comprehensive income (loss) $ 3,947 $ ( 364 )
Schedule of projected benefit obligations, accumulated benefit obligation and fair value of plan assets where accumulated benefit obligation exceeded fair value of plan assets	The following table presents the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for this defined benefit pension plan where accumulated benefit obligation exceeded the fair value of plan assets (in thousands): June 30, 2022 2021 Projected benefit obligation $ 17,453 $ 18,705 Accumulated benefit obligation $ 15,546 $ 16,891 Fair value of plan assets $ 17,350 $ 14,419
Schedule Of Net Benefit Costs And Other Amounts Recognized In Other Comprehensive Income Loss Table Text Block	The following table shows the components of the Company’s net periodic benefit costs and the other amounts recognized in other comprehensive loss, before tax, related to the Company’s defined benefit pension plan (in thousands): Year ended June 30, 2022 2021 2020 Net Periodic Benefit Costs: Service cost $ 1,513 $ 1,766 $ 2,003 Interest cost 75 38 62 Expected returns on assets ( 144 ) ( 142 ) ( 151 ) Amortization of prior service cost 54 54 ( 2 ) Amortization of net loss — — — Settlement charges — — 178 Net periodic benefit costs 1,498 1,716 2,090 Other Amounts Recognized in Other Comprehensive Loss: Net (gain) loss arising during the year ( 3,584 ) ( 850 ) ( 593 ) Prior service cost ( 53 ) ( 54 ) 2 Amortization of prior service cost ( 678 ) 24 1,005 Amortization of net gain — — — Effect of settlement 4 8 ( 178 ) Total recognized in other comprehensive (gain) loss ( 4,311 ) ( 872 ) 236 Total recognized in net periodic benefit costs and other $ ( 2,813 ) $ 844 $ 2,326
Schedule of amounts in accumulated other comprehensive loss that are expected to be recognized	The amounts in accumulated other comprehensive loss that are expected to be recognized as components of net periodic benefit cost during fiscal year 2023 related to the Company’s defined benefit pension plan are as follows (in thousands): 2023 Net gain $ 172 Prior service credit 24 Accumulated other comprehensive income $ 196
Schedule of assumptions used to determine net periodic benefit cost and benefit obligation	The assumptions used to determine net periodic benefit cost and to compute the expected long‑term return on assets for the Company’s defined benefit pension plan were as follows: Fiscal Years 2022 2021 2020 Net Periodic Benefit Costs: Discount rate 1.90 % 0.40 % 0.25 % Rate of compensation increase 1.75 % 1.50 % 1.50 % Expected long-term return on assets 1.00 % 1.00 % 1.00 % The assumptions used to measure the benefit obligation for the Company’s defined benefit pension plan were as follows: June 30, 2022 2021 Benefit Obligation: Discount rate 1.90 % 0.40 % Rate of compensation increase 1.75 % 1.50 %
Schedule of estimated future benefit payments	Estimated future benefit payments expected to be paid by the defined benefit pension plan at June 30, 2022 are as follows (in thousands): Year Ending June 30, Future 2023 $ 1,001 2024 1,015 2025 1,212 2026 1,054 2027 1,218 Thereafter 8,605 Total $ 14,105

Segment Disclosure (Tables)

Segment Disclosure (Tables)	12 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Years ended June 30, 2022 2021 2020 Americas $ 126,005 $ 105,878 $ 128,562 Europe, Middle East, India and Africa 134,640 121,568 119,989 Asia Pacific, excluding Japan and China 28,953 26,425 31,297 Japan 53,376 62,636 72,688 China 86,935 79,782 30,392 Total $ 429,909 $ 396,289 $ 382,928
Schedule of Geographic Areas in Which the Company has Long Lived Tangible Assets	Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands): June 30, June 30, Americas $ 11,251 $ 10,588 Europe, Middle East, India and Africa 228 265 Asia Pacific, excluding Japan and China 272 170 Japan 265 701 China 669 608 Total $ 12,685 $ 12,332

The Company and its Significa_4

The Company and its Significant Accounting Policies - Additional Information (Details) shares in Millions	12 Months Ended
	Jun. 30, 2022 USD ($) Segment Customer shares	Jun. 30, 2021 USD ($) Customer shares	Jun. 30, 2020 USD ($) Customer shares
Concentration Risk [Line Items]
Capitalized development of software costs | $	$ 0
Number of operating segments | Segment	1
Number of reporting units | Segment	1
Impairment of goodwill | $	$ 0	$ 0	$ 0
Advertising expenses | $	$ 200,000	$ 200,000	$ 200,000
Subsequent period within which no material changes in unrecognized tax benefits are expected	12 months
Stock options
Concentration Risk [Line Items]
Expiration period	10 years
Machinery and equipment
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	5 years
Furniture and fixtures
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	4 years
Computer and office equipment
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	3 years
Computer Software
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	3 years
Total net revenue | Customer concentration risk | Maximum
Concentration Risk [Line Items]
Number of significant customers | Customer			0
Total net revenue | Customer concentration risk | Minimum
Concentration Risk [Line Items]
Number of significant customers | Customer	1	1
Total net revenue | Customer one | Customer concentration risk
Concentration Risk [Line Items]
Percentage of concentration risk	10%	10%
Total net revenue | No customer | Customer concentration risk
Concentration Risk [Line Items]
Percentage of concentration risk			10%
Total accounts receivable | Credit concentration risk
Concentration Risk [Line Items]
Number of significant customers | Customer	2	2
Total accounts receivable | Customer two | Credit concentration risk | Minimum
Concentration Risk [Line Items]
Percentage of concentration risk	10%	10%
3.75% Convertible Notes Due July 2022
Concentration Risk [Line Items]
Interest rate (as a percent)	3.75%	3.75%	3.75%
Convertible debt maturity period	2022-07
Common stock not included in the calculation of potentially diluted shares | shares	0.5	0.5	14.9
3.75% Convertible Notes Due June 2026
Concentration Risk [Line Items]
Interest rate (as a percent)	3.75%
Convertible debt maturity period	2026-06
Common stock not included in the calculation of potentially diluted shares | shares	17.1

The Company and its Significa_5

The Company and its Significant Accounting Policies - Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net income (loss) used to compute basic and diluted loss per share	$ (5,347)	$ (6,311)	$ 3,827
Denominator:
Weighted average shares used to compute basic income (loss) per share	92,095	92,031	89,874
Weighted average shares used to compute diluted income (loss) per share	92,095	92,031	90,623

The Company and its Significa_6

The Company and its Significant Accounting Policies - Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per common share (Details) - shares shares in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income (loss) per share (in shares)	12,828	10,228	9,717
Stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income (loss) per share (in shares)	7,053	7,030	5,956
RSUs, PSUs and MSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income (loss) per share (in shares)	5,775	3,198	3,761

Recent Accounting Pronounceme_3

Recent Accounting Pronouncements - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021	May 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Increase to accumulated deficit	$ (492,522)		$ (488,024)
Decrease to additional paid in capital	$ 543,211		$ 554,680
Accounting Standards Update 2020-06
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Increase to accumulated deficit		$ 800
Decrease to additional paid in capital		25,600
Increase to convertible debt, current		$ 24,800
3.75% Convertible Notes Due June 2026
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer, Asset and Liability (Details) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Assets:
Unbilled accounts receivable – current	[1]	$ 13,325	$ 12,354
Interest receivable – current	[2]	493	512
Long-term accounts receivable	[3]	5,301	4,970
Interest receivable – non-current	[3]	683	1,083
Liabilities:
Customer advances		25,290	24,937
Deferred revenue – current		75,375	81,660
Deferred revenue – non-current		24,694	$ 23,685
Change in assets, value:
Change in unbilled accounts receivable – current, value	[1]	971
Change in interest receivable – current, value	[2]	(19)
Change in long-term accounts receivable, value	[3]	331
Change in Interest receivable – non-current, value	[3]	(400)
Change in liabilities, value:
Change in customer advances, value		353
Change in deferred revenue – current, value		(6,285)
Change in deferred revenue – non-current, value		$ 1,009
Change in assets, percentage:
Change in unbilled accounts receivable – current, percentage	[1]	8%
Change in interest receivable – current, percentage	[2]	(4.00%)
Change in long-term accounts receivable, percentage	[3]	7%
Change in Interest receivable – non-current, percentage	[3]	(37.00%)
Change in liabilities, percentage:
Change in customer advances, percentage		1%
Change in deferred revenue – current, percentage		(8.00%)
Change in deferred revenue – non-current, percentage		4%
[1] Included in accounts receivable on consolidated balance sheets Included in prepaid expenses and other current assets on consolidated balance sheets Included in other assets on consolidated balance sheets

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Recognition of deferred revenue	$ 81.2	$ 107.3
Remaining performance obligations amount	1,104.4
Amount recognized on open system sales contracts	$ 983.2
Percentage of changes in operating results on entity's revenue	16%
Capitalized costs to obtain a contract	$ 11.4	8.9
Impairment loss	0.6	0.6
Capitalized contract cost, amortization	3.3	$ 2.8
Long-term Warranty and Service
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	69.1
Performance Obligations Other Than Warrant
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	$ 1,035.3

Revenue - Schedule of Remaining

Revenue - Schedule of Remaining Performance Obligations related to Warranty (Details) - Long-term Warranty and Service $ in Thousands	Jun. 30, 2022 USD ($)
2023	$ 30,741
2024	20,491
2025	9,071
Thereafter	$ 8,797

Revenue - Additional Informat_2

Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-07-01	Jun. 30, 2022
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations recognized period	12 months
Minimum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	25%
Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	28%

Supplemental Financial Inform_3

Supplemental Financial Information - Schedule of Accounts Receivable, Net (Details) - USD ($) $ in Thousands		Jun. 30, 2022	Jun. 30, 2021
Accounts receivable, net
Accounts receivable		$ 82,117	$ 74,054
Unbilled fees and services	[1]	13,325	12,354
Accounts and other receivable, gross		95,442	86,408
Less: Allowance for credit losses		(1,000)	(1,048)
Accounts receivable, net	[2]	$ 94,442	$ 85,360
[1] Included in accounts receivable on consolidated balance sheets Included accounts receivable from the China joint venture of $ 24,828 and $ 8,822 at June 30, 2022 and June 30, 2021, respectively. See Note 13

Supplemental Financial Inform_4

Supplemental Financial Information - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Accounts receivable, net
Allowance for credit losses, payments and credits	$ 300,000	$ 800,000
Allowance for credit losses, additions	600,000	700,000
Allowance for credit losses, write-offs	300,000	200,000
Financing receivables
Accounts receivable with contractual maturities of more than one year	2,759,000	3,387,000
Adjustments to allowance for credit loss	0	3,400,000
Financing receivables, additions	0	200,000
Financing receivables, write-offs	0	3,600,000
Property and equipment, net
Depreciation expense	$ 5,400,000	$ 6,200,000	$ 7,300,000

Supplemental Financial Inform_5

Supplemental Financial Information - Summary of Financing Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Financing receivables
Financing receivable	$ 6,137	$ 7,102
Allowance for credit losses	(943)	(943)
Total, net	5,194	6,159
Current	2,435	2,772
Non-current	$ 2,759	$ 3,387

Supplemental Financial Inform_6

Supplemental Financial Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Inventory, Net [Abstract]
Raw materials	$ 61,871	$ 45,301
Work-in-process	16,367	22,014
Finished goods	64,016	58,614
Inventories	$ 142,254	$ 125,929

Supplemental Financial Inform_7

Supplemental Financial Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Property and equipment, net
Property and equipment, gross	$ 91,895	$ 90,507
Less: Accumulated depreciation	(79,210)	(78,175)
Property and equipment, net	12,685	12,332
Furniture and Fixtures
Property and equipment, net
Property and equipment, gross	1,766	1,636
Computer and Office Equipment
Property and equipment, net
Property and equipment, gross	8,605	8,972
Software
Property and equipment, net
Property and equipment, gross	5,344	7,477
Leasehold Improvements
Property and equipment, net
Property and equipment, gross	26,659	26,102
Machinery and Equipment
Property and equipment, net
Property and equipment, gross	46,522	45,265
Construction in Progress
Property and equipment, net
Property and equipment, gross	$ 2,999	$ 1,055

Supplemental Financial Inform_8

Supplemental Financial Information - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss)
Balance	$ 68,840	$ 63,635
Balance	53,189	68,840
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss)
Balance	2,457	752
Other comprehensive loss	(3,998)	1,705
Balance	(1,541)	2,457
Change in Defined Pension Benefit Obligation
Accumulated Other Comprehensive Income (Loss)
Balance	(364)	(1,236)
Other comprehensive loss	4,311	872
Balance	3,947	(364)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Balance	2,093	(484)
Other comprehensive loss	313	2,577
Balance	$ 2,406	$ 2,093

Supplemental Financial Inform_9

Supplemental Financial Information - Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Supplemental Financial Information Disclosure [Abstract]
Interest expense	$ (8,129)	$ (16,893)	$ (18,080)
Foreign currency transaction loss	(2,618)	(1,953)	(2,343)
Gain on contribution to joint venture	0	0	12,964
Loss on Debt Extinguishment	0	(9,948)
Other expense, net	356	1,128	759
Total other expense, net	$ (10,391)	$ (27,666)	$ (6,700)

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating lease costs	$ 9.2	$ 9.1
Short-term operating lease costs	0.4	0.2
Cash paid for amounts included in the measurement of operating lease liabilities	9.8	9.7
Operating lease liabilities arising from obtaining operating right of-use assets	$ 3.2	$ 1.1
Weighted average remaining lease term	2 years 7 months 2 days
Weighted average discount rate	6.07%

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Beginning balance operating lease right-of-use asset	$ 22,522	$ 28,647
Lease asset added	3,522	1,069
Amortization for the year	(9,246)	(7,194)
Ending balance operating lease right-of-use asset	16,798	22,522
Beginning balance operating lease obligation	25,609	32,397
Lease liability added	3,209	1,069
Repayment and interest accretion	(9,798)	(7,857)
Ending balance operating lease obligation	19,020	25,609
Operating lease liabilities, current	8,567	8,169
Operating lease liabilities, non-current	$ 10,453	$ 17,441

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Leases [Abstract]
2023	$ 9,554
2024	6,770
2025	3,631
2026	354
2027	197
Total operating lease payments	20,506
Less: imputed interest	(1,486)
Present value of operating lease liabilities	$ 19,020

Goodwill and Purchased Intang_3

Goodwill and Purchased Intangible Assets - Schedule of Goodwill and Changes in the Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 57,960	$ 57,717
Currency translation adjustment	(120)	243
Balance at the end of the period	$ 57,840	$ 57,960

Goodwill and Purchased Intang_4

Goodwill and Purchased Intangible Assets - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2017
Finite Lived Intangible Assets [Line Items]
Impairment of goodwill	$ 0	$ 0	$ 0
Purchase of intangible assets	0	0	170,000
Amortization expense	$ 100,000	$ 200,000	$ 200,000
Patent license
Finite Lived Intangible Assets [Line Items]
Useful Lives			2 years	7 years
Purchase of intangible assets			$ 200,000

Goodwill and Purchased Intang_5

Goodwill and Purchased Intangible Assets - Schedule of Intangible Assets Associated with Purchased Patent License (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2020	Jun. 30, 2017	Jun. 30, 2021
Finite Lived Intangible Assets [Line Items]
Net Amount	$ 250			$ 435
Patent license
Finite Lived Intangible Assets [Line Items]
Useful Lives		2 years	7 years
Gross Carrying Amount	1,170			1,170
Accumulated Amortization	(920)			(735)
Net Amount	$ 250			$ 435
Patent license | Minimum
Finite Lived Intangible Assets [Line Items]
Useful Lives	2 years
Patent license | Maximum
Finite Lived Intangible Assets [Line Items]
Useful Lives	7 years

Goodwill and Purchased Intang_6

Goodwill and Purchased Intangible Assets - Schedule of Estimated Future Amortization Expense of Purchased Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Estimated future amortization expense of purchased intangible assets
2023	$ 143
2024	107
Net Amount	$ 250	$ 435

Derivative Financial Instrume_3

Derivative Financial Instruments - Additional Information (Details)	12 Months Ended
	Jun. 30, 2022
Maximum
Length of forward contracts	three months

Derivative Financial Instrume_4

Derivative Financial Instruments - Summary of Outstanding Forward Currency Exchange Contracts (Details) - Forward Currency Exchange Contracts - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Outstanding forward currency exchange contracts	$ 68,335,000	$ 54,201,000
Canadian Dollar
Outstanding forward currency exchange contracts	0	527,000
Swiss Franc
Outstanding forward currency exchange contracts	27,910,000	8,891,000
Chinese Yuan
Outstanding forward currency exchange contracts	2,524,000	1,927,000
Euro
Outstanding forward currency exchange contracts	16,307,000	19,037,000
British Pound
Outstanding forward currency exchange contracts	3,699,000	3,191,000
Indian Rupee
Outstanding forward currency exchange contracts	3,728,000	7,825,000
Japanese Yen
Outstanding forward currency exchange contracts	$ 14,167,000	$ 12,803,000

Derivative Financial Instrume_5

Derivative Financial Instruments - Schedule of Gain (Loss) Associated with the Company's Derivative Financial Instruments (Details) - Other expense, net - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Foreign currency exchange gain (loss) on forward contracts	$ (887)	$ 396	$ (3,087)
Forward contracts
Foreign currency exchange gain (loss) on forward contracts	$ (2,045)	$ (2,349)	$ 744

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - Forward Currency Exchange Contracts - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Financial assets
Outstanding forward currency exchange contracts	$ 68,335,000	$ 54,201,000
Level 2
Financial assets
Fair value of currency contract based on exchange rate	$ 68,300,000	$ 54,200,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Carrying Value
Fair value measurement
Long term debt	$ 180,470	$ 173,797
Fair Value
Fair value measurement
Long term debt	161,278	210,024
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes Due 2022
Fair value measurement
Long term debt	2,863	2,712
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	97,619	72,388
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes Due 2022
Fair value measurement
Long term debt	2,729	3,164
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	78,561	108,163
Term Loan Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	74,988	78,697
Term Loan Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	74,988	78,697
Revolving Credit Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	5,000	20,000
Revolving Credit Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	$ 5,000	$ 20,000

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Parenthetical) (Details)	Jun. 30, 2022	Jul. 01, 2021	Jun. 30, 2021	May 31, 2021	Aug. 31, 2017
3.75% Convertible Notes Due 2022
Fair value measurement
Interest rate (as a percent)	3.75%		3.75%	3.75%	3.75%
3.75% Convertible Notes Due 2026
Fair value measurement
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
License agreement | WARF (Wisconsin Alumni Research Foundation)
Loss Contingencies [Line Items]
Royalty costs	$ 1.9	$ 1.9	$ 2.5
Royalty amount accrued	2.4	2.3
Financial Guarantee | Various Customers
Loss Contingencies [Line Items]
Bank guarantees	$ 1.2	$ 1.2
3.75% Convertible Notes due 2022
Loss Contingencies [Line Items]
Interest rate (as a percent)	3.75%
3.75% Convertible Notes Due 2026
Loss Contingencies [Line Items]
Interest rate (as a percent)	3.75%

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Long-term Principal and Interest on Notes and New Credit Facilities (Details) $ in Thousands	Jun. 30, 2022 USD ($)	[1]
Long-term principal and interest on Convertible Notes
2023	$ 16,266
2024	13,138
2025	14,827
2026	116,777
Total	$ 161,008
[1] These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company’s consolidated balance sheet. Any conversion, premium, redemption or purchase of the Notes that would impact cash payments noted in the preceding table.

Debt - Additional Information (

Debt - Additional Information (Details)

1 Months Ended

3 Months Ended

12 Months Ended

May 14, 2021 USD ($)

May 06, 2021 USD ($)

Jun. 14, 2017 USD ($)

May 31, 2021 USD ($)

Aug. 31, 2019 USD ($)

Jul. 31, 2019

May 31, 2019 USD ($)

Apr. 30, 2019

Dec. 31, 2018 USD ($)

Dec. 31, 2017 USD ($)

Jun. 30, 2021 USD ($)

Jun. 30, 2022 USD ($) $ / shares

Jun. 30, 2021 USD ($)

Jul. 01, 2021 USD ($)

Aug. 31, 2017 USD ($)

Apr. 30, 2014

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 0

$ 9,948,000

Debt discount costs

0

Principal amount of the Notes

183,865,000

Unamortized debt costs

3,395,000

Increase to accumulated deficit

$ (488,024,000)

(492,522,000)

(488,024,000)

Decrease to additional paid in capital

554,680,000

543,211,000

554,680,000

Revolving Credit Facility

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 1,400,000

Initial borrowing capacity

$ 52,000,000

Minimum drawn balance (as a percent)

30%

Principal amount of the Notes

5,000,000

Term loan

Debt Instrument [Line Items]

Principal amount of the Notes

80,000,000

76,000,000

80,000,000

New Revolving Credit Facility

Debt Instrument [Line Items]

Initial borrowings

25,000,000

Principal amount of the Notes

20,000,000

5,000,000

20,000,000

Unamortized debt costs

$ 1,300,000

$ 1,000,000

$ 1,300,000

90-day LIBOR | Revolving Credit Facility

Debt Instrument [Line Items]

Interest rate determination basis

90-day LIBOR

Variable rate (as a percent)

4.50%

3.50%

4.50%

3.75% Convertible Notes Due 2022

Debt Instrument [Line Items]

Aggregate principal amount of debt issued

$ 85,000,000

Interest rate (as a percent)

3.75%

3.75%

3.75%

3.75%

3.75%

Conversion rate, number of shares to be issued per $1000 of principal amount (in shares)

174.8252

Principal amount used for debt instrument conversion ratio

$ 1,000

Conversion price (in dollars per share) | $ / shares

$ 5.72

Repurchase price, as a percentage of the principal amount, in the event of a fundamental change, as defined in Indenture

100%

Convertible notes exchanged

$ 82,100,000

Convertible notes, aggregate principal amount outstanding

$ 2,900,000

$ 2,900,000

$ 2,900,000

Loss on extinguishment of debt

4,300,000

Extinguishment of equity component

14,500,000

Settlement consideration paid

96,000,000

Debt instrument, fair value of liability component

81,500,000

Debt discount costs

0

Principal amount of the Notes

2,865,000

Unamortized debt costs

$ 1,000

3.50% Convertible Notes Due 2018

Debt Instrument [Line Items]

Interest rate (as a percent)

3.50%

3.50% Series A Convertible Senior Notes Due 2018

Debt Instrument [Line Items]

Interest rate (as a percent)

3.50%

3.75% Convertible Notes Due 2026

Debt Instrument [Line Items]

Aggregate principal amount of debt issued

$ 100,000,000

Interest rate (as a percent)

3.75%

3.75%

3.75%

3.75%

3.75%

Conversion rate, number of shares to be issued per $1000 of principal amount (in shares)

170.5611

Principal amount used for debt instrument conversion ratio

$ 1,000

Conversion price (in dollars per share) | $ / shares

$ 5.86

Repurchase price, as a percentage of the principal amount, in the event of a fundamental change, as defined in Indenture

100%

Convertible notes exchanged

$ 97,100,000

Convertible notes, aggregate principal amount outstanding

$ 100,000,000

$ 100,000,000

$ 100,000,000

Convertible notes, aggregate principal amount issued for cash

$ 2,900,000

Debt discount costs

0

Principal amount of the Notes

100,000,000

Unamortized debt costs

$ 2,381,000

3.75% Convertible Notes Due 2026 | New Qualified Investors

Debt Instrument [Line Items]

Interest rate (as a percent)

3.75%

3.75%

Extinguishment of equity component

$ 25,900,000

Debt instrument, fair value of liability component

74,100,000

Convertible notes, aggregate principal amount issued for cash

2,900,000

Reduction in debt issuance cost allocated to additional paid in capital

$ 700,000

Increase to accumulated deficit

$ 800,000

Decrease to additional paid in capital

25,600,000

Increase to convertible debt, current

$ 24,800,000

3.75% Convertible Notes due 2022 and 3.75% Convertible Notes due 2026

Debt Instrument [Line Items]

Interest rate (as a percent)

3.75%

Discounts, issuance costs and third party costs

$ 25,600,000

Issuance costs attributable to liability component amortized

$ 800,000

Exchange | 3.75% Convertible Notes Due 2022

Debt Instrument [Line Items]

Aggregate principal amount of debt issued

$ 53,000,000

Exchange | 3.50% Convertible Notes due 2018 and 3.5% Series A Senior Notes due 2018

Debt Instrument [Line Items]

Aggregate principal amount of debt issued

47,000,000

Repurchase

Debt Instrument [Line Items]

Repurchase/Retirement of existing notes

28,000,000

Repurchase | 3.75% Convertible Notes Due 2022

Debt Instrument [Line Items]

Aggregate principal amount of debt issued

$ 32,000,000

Prior Revolving Credit Agreement | Revolving Credit Facility

Debt Instrument [Line Items]

Reduced borrowing capacity

$ 32,000,000

Prior Term Loan

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 4,300,000

Prior Term Loan | Term Loan Facility

Debt Instrument [Line Items]

Initial term loan borrowing capacity

40,000,000

Additional term loan borrowing capacity

$ 20,000,000

Loan prepayment fees for first year (percentage)

3%

Loan prepayment fees for second year (percentage)

2%

Loan prepayment fees for third year (percentage)

1%

Term of loan

60 months

Term of interest payable (in months)

24 months

Administrative fee payable on term loan as a percentage

0.25%

Final payment of administrative fee payable on term loan as a percentage

4%

Debt instrument amount withdrawn

$ 5,000,000

Debt instrument scheduled commitment extended termination date

Jun. 30, 2019

Debt instrument remaining unfunded commitment amount

$ 15,000,000

Debt instrument increased commitment amount

$ 25,000,000

$ 500,000

Debt discount costs

$ 1,600,000

$ 1,500,000

Prior Term Loan | 90-day LIBOR | Term Loan Facility

Debt Instrument [Line Items]

Interest rate determination basis

90-day LIBOR

Variable rate (as a percent)

6.75%

5.50%

5.50%

6.75%

6.75%

Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 3.00:1.00

Debt Instrument [Line Items]

Variable rate (as a percent)

3.25%

Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 2.00:1.00 But Less Than 3.00:1.00

Debt Instrument [Line Items]

Variable rate (as a percent)

3%

Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 1.00:1.00 But Less Than 2.00:1.00

Debt Instrument [Line Items]

Variable rate (as a percent)

2.75%

Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Less Than 1.00:1.00

Debt Instrument [Line Items]

Variable rate (as a percent)

2.50%

Senior Secured Credit Agreement | Term loan

Debt Instrument [Line Items]

Term of loan

5 years

Credit facility borrowing capacity

$ 80,000,000

Senior Secured Credit Agreement | New Revolving Credit Facility

Debt Instrument [Line Items]

Credit facility borrowing capacity

$ 40,000,000

Senior Secured Credit Agreement | New Credit Agreement

Debt Instrument [Line Items]

Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility

0.35%

Senior Secured Credit Agreement | New Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 3.00:1.00

Debt Instrument [Line Items]

Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility

0.40%

Senior Secured Credit Agreement | New Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 2.00:1.00 But Less Than 3.00:1.00

Debt Instrument [Line Items]

Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility

0.35%

Senior Secured Credit Agreement | New Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 1.00:1.00 But Less Than 2.00:1.00

Debt Instrument [Line Items]

Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility

0.30%

Senior Secured Credit Agreement | New Credit Agreement | Consolidated Senior Net Leverage Ratio is Less Than 1.00:1.00

Debt Instrument [Line Items]

Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility

0.25%

Senior Secured Credit Agreement | New Credit Agreement | If all or Portion of Loans Under New Term Loan Facility are Prepaid

Debt Instrument [Line Items]

Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility

1%

Senior Secured Credit Agreement | 90-day LIBOR

Debt Instrument [Line Items]

Interest rate determination basis

90-day LIBOR

Variable rate (as a percent)

3%

Senior Secured Credit Agreement | 90-day LIBOR | Floor Rate

Debt Instrument [Line Items]

Variable rate (as a percent)

0.50%

Debt - Schedule of Carrying Val

Debt - Schedule of Carrying Values of All Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Principal amount of the Notes	$ 183,865
Unamortized debt costs	(3,395)
Unamortized debt discount	0
Net carrying amount	180,470
Reported as:
Short-term debt	8,563
Long-term debt	171,907	$ 170,007
Net carrying amount	180,470
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount of the Notes	5,000
Net carrying amount	5,000
Reported as:
Net carrying amount	5,000
3.75% Convertible Notes Due 2022
Debt Instrument [Line Items]
Principal amount of the Notes	2,865
Unamortized debt costs	(1)
Unamortized debt discount	0
Net carrying amount	2,864
Reported as:
Net carrying amount	2,864
3.75% Convertible Notes Due 2026
Debt Instrument [Line Items]
Principal amount of the Notes	100,000
Unamortized debt costs	(2,381)
Unamortized debt discount	0
Net carrying amount	97,619
Reported as:
Net carrying amount	97,619
Term Loan Facility due December 2022
Debt Instrument [Line Items]
Principal amount of the Notes	76,000
Unamortized debt costs	(1,013)
Net carrying amount	74,987
Reported as:
Net carrying amount	$ 74,987

Debt - Summary of interest expe

Debt - Summary of interest expense on New Credit Facilities and Convertible Notes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Debt Disclosure [Abstract]
Interest expense related to contractual interest coupon	$ 7,233	$ 10,590	$ 12,373
Interest expense related to amortization of debt discount	0	4,887	4,168
Interest expense related to amortization of debt issuance costs	909	1,356	1,350
Interest expense related to extinguishment of debt	0	9,948
Total	$ 8,142	$ 26,781	$ 17,891

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	May 07, 2021	Jun. 30, 2021	Jun. 30, 2022	May 05, 2021
Class of Stock [Line Items]
Number of shares of common stock reserved for issuance under stock incentive plans and employee stock purchase plan			1,600,000
Repurchased common stock	3,108,369
Aggregate amount of shares repurchased	$ 14,100	$ 14,081
Maximum
Class of Stock [Line Items]
Authorized repurchase of common stock				18,000,000

Stock Incentive Plan and Empl_3

Stock Incentive Plan and Employee Stock Purchase Plan - Additional Information (Details)	12 Months Ended
	Jun. 30, 2022 USD ($) Item Plan $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock incentive plans | Plan	2
Fair value of common stock (in dollars per share) | $ / shares	$ 1.96
Share-based compensation expense	$ 10,600,000	$ 9,332,000	$ 8,152,000
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 1,300,000	$ 1,400,000	$ 1,100,000
Weighted average period for recognition of compensation costs	7 months 6 days
Unrecognized compensation cost	$ 400,000
Purchase price expressed as percentage of fair market value of common stock	85%
Shares issued under the ESPP | shares	1,100,000	1,200,000	1,100,000
Weighted average fair value (in dollars per share) | $ / shares	$ 4.33	$ 1.90		$ 2.16
Maximum | ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Payroll deductions as percentage of salaries	10%
Number of shares per period up to which employees may purchase | shares	2,500
Value of shares up to which employees may purchase in any calendar year	$ 25,000
Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of options exercised	300,000	$ 200,000	$ 0
Share-based compensation expense	2,600,000	2,400,000	2,000,000
Realized excess tax benefits related to stock options exercises	0	0	0
Unrecognized compensation cost related to unvested stock options, net of estimated forfeitures	$ 3,100,000
Weighted average period for recognition of compensation costs	2 years 4 months 24 days
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 6,700,000	$ 5,400,000	$ 4,900,000
Weighted average period for recognition of compensation costs	2 years 2 months 12 days
Unrecognized compensation cost	$ 11,000,000
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 3.75	$ 4.16	$ 2.74
Aggregate fair market value of units vested	$ 6,400,000
Granted (in shares) | shares	3,236,000	1,738,000	2,009,000
Vested (in shares) | shares	1,341,000	1,452,000	1,579,000
Cancelled/Forfeited (in shares) | shares	252,000	539,000	343,000
Performance Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted (in shares) | shares	937,000	280,000	419,000
Vested (in shares) | shares	0	0
Cancelled (in shares) | shares	642,000	419,000	0
Share-based compensation expense (benefit)	$ 0	$ 0	$ 0
Cancelled/Forfeited (in shares) | shares	642,000	419,000
Market Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 0	$ 100,000	$ 200,000
Unrecognized compensation cost		$ 0
Granted (in shares) | shares	0	0	0
Vested (in shares) | shares	0	0	0
Cancelled/Forfeited (in shares) | shares	0	171,000	470,000
2007 Amended and Restated Plan | Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual term	10 years
Percentage of the award vesting at first anniversary	25%
Vesting period for first 25% vesting rights	1 year
Remainder vesting period	36 months
2007 Amended and Restated Plan | Stock options | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as a percentage of fair market value on the grant date	100%
2007 Amended and Restated Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of the award vesting at first anniversary	50%
Percentage of the award vesting at second anniversary	50%
2007 Amended and Restated Plan | Time-based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Annual vesting percentage	25%
MSU Program | Market Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 0	$ 0
Number of measurement periods | Item	2
MSU Program | Market Stock Units | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Target number of shares that participating executives may earn (as a percent)	150%

Stock Incentive Plan and Empl_4

Stock Incentive Plan and Employee Stock Purchase Plan - Summary of Share-based Compensation Charges Included in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Share-based compensation expenses
Share-based compensation expense	$ 10,600	$ 9,332	$ 8,152
Cost of revenue
Share-based compensation expenses
Share-based compensation expense	1,584	1,296	1,244
Research and development
Share-based compensation expenses
Share-based compensation expense	1,371	1,348	1,457
Selling and marketing
Share-based compensation expenses
Share-based compensation expense	2,213	1,457	1,159
General and administrative
Share-based compensation expenses
Share-based compensation expense	$ 5,432	$ 5,231	$ 4,292

Stock Incentive Plan and Empl_5

Stock Incentive Plan and Employee Stock Purchase Plan - Schedule of Assumptions Used for Determining Fair Value of Stock Options (Details) - Stock options	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Weighted average assumptions used for determining fair value of options
Risk-free interest rate, Minimum (as a percent)	2.71%	0.59%	1.14%
Risk-free interest rate, Maximum (as a percent)	3.21%	1.27%	1.53%
Expected volatility, Minimum (as a percent)	54.10%	54.70%	47.30%
Expected volatility, Maximum (as a percent)	57.30%	55.60%	48.90%
Minimum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	7 years 3 months 18 days	6 years 8 months 19 days	5 years 7 months 17 days
Maximum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	8 years 11 months 8 days	6 years 10 months 17 days	5 years 7 months 20 days

Stock Incentive Plan and Empl_6

Stock Incentive Plan and Employee Stock Purchase Plan - Schedule of Option Activity Under the Company's Incentive Plan (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Options Outstanding
Balance at the beginning of the year (in shares)	7,030	5,956	5,220
Options granted (in shares)	756	1,526	2,305
Options exercised (in shares)	(331)	(209)
Options forfeited/expired (in shares)	(402)	(243)	(1,569)
Balance at the end of the year (in shares)	7,053	7,030	5,956	5,220
Vested or Expected to vest at the end of the year (in shares)	7,053
Exercisable at the end of the year (in shares)	4,576
Weighted Average Exercise Price
Balance at the beginning of the year (in dollars per share)	$ 3.93	$ 3.82	$ 4.50
Options granted (in dollars per share)	2.05	4.48	2.64
Options exercised (in dollars per share)	3.69	4.09
Options forfeited/expired (in dollars per share)	4.05	4.40	4.36
Balance at the end of the year (in dollars per share)	3.73	$ 3.93	$ 3.82	$ 4.50
Vested or Expected to vest at the end of the year (in dollars per share)	3.73
Exercisable at the end of the year (in dollars per share)	$ 4
Weighted Average Remaining Contractual Life (In Years)
Balance	7 years 18 days	7 years 7 months 28 days	8 years 14 days	7 years 11 months 19 days
Vested or Expected to vest at the end of the year	7 years 18 days
Exercisable at the end of the year	6 years 3 months 7 days
Aggregate Intrinsic Value (in thousands)
Balance at the beginning of the year		$ 5,036	$ 0	$ 11
Exercisable at the end of the year	$ 0

Stock Incentive Plan and Empl_7

Stock Incentive Plan and Employee Stock Purchase Plan - Summary of Information about Outstanding and Exercisable Options (Details) - Stock options	12 Months Ended
	Jun. 30, 2022 $ / shares shares
Options Outstanding
Number Outstanding | shares	7,053,000
Weighted-Average Remaining Contractual Life (Years)	7 years 18 days
Weighted-Average Exercise Price (in dollars per share)	$ 3.73
Options Exercisable
Number Outstanding | shares	4,576,000
Weighted-Average Exercise Price (in dollars per share)	$ 4
$1.96 - 2.08
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	1.96
Exercise price, high end of range (in dollars per share)	$ 2.08
Options Outstanding
Number Outstanding | shares	756,000
Weighted-Average Remaining Contractual Life (Years)	9 years 11 months 8 days
Weighted-Average Exercise Price (in dollars per share)	$ 2.05
Options Exercisable
Number Outstanding | shares	0
Weighted-Average Exercise Price (in dollars per share)	$ 0
$2.60-2.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	2.60
Exercise price, high end of range (in dollars per share)	$ 2.60
Options Outstanding
Number Outstanding | shares	1,533,000
Weighted-Average Remaining Contractual Life (Years)	7 years 4 months 2 days
Weighted-Average Exercise Price (in dollars per share)	$ 2.60
Options Exercisable
Number Outstanding | shares	1,022,000
Weighted-Average Exercise Price (in dollars per share)	$ 2.60
$2.97 - 4.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	2.97
Exercise price, high end of range (in dollars per share)	$ 4
Options Outstanding
Number Outstanding | shares	623,000
Weighted-Average Remaining Contractual Life (Years)	6 years 5 months 1 day
Weighted-Average Exercise Price (in dollars per share)	$ 3.52
Options Exercisable
Number Outstanding | shares	500,000
Weighted-Average Exercise Price (in dollars per share)	$ 3.65
$4.10 - 4.10
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	4.10
Exercise price, high end of range (in dollars per share)	$ 4.10
Options Outstanding
Number Outstanding | shares	2,048,000
Weighted-Average Remaining Contractual Life (Years)	6 years 5 months 1 day
Weighted-Average Exercise Price (in dollars per share)	$ 4.10
Options Exercisable
Number Outstanding | shares	1,835,000
Weighted-Average Exercise Price (in dollars per share)	$ 4.10
$4.46 - 4.46
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	4.46
Exercise price, high end of range (in dollars per share)	$ 4.46
Options Outstanding
Number Outstanding | shares	1,113,000
Weighted-Average Remaining Contractual Life (Years)	8 years 5 months 1 day
Weighted-Average Exercise Price (in dollars per share)	$ 4.46
Options Exercisable
Number Outstanding | shares	441,000
Weighted-Average Exercise Price (in dollars per share)	$ 4.46
$4.52 - 6.96
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	4.52
Exercise price, high end of range (in dollars per share)	$ 6.96
Options Outstanding
Number Outstanding | shares	980
Weighted-Average Remaining Contractual Life (Years)	4 years 6 months 3 days
Weighted-Average Exercise Price (in dollars per share)	$ 5.36
Options Exercisable
Number Outstanding | shares	778
Weighted-Average Exercise Price (in dollars per share)	$ 5.44

Stock Incentive Plan and Empl_8

Stock Incentive Plan and Employee Stock Purchase Plan - Summary of Activity of RSUs, PSUs and MSUs (Details) - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Restricted Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)	2,918,000	3,171,000	3,084,000
Granted (in shares)	3,236,000	1,738,000	2,009,000
Vested (in shares)	(1,341,000)	(1,452,000)	(1,579,000)
Cancelled/Forfeited (in shares)	(252,000)	(539,000)	(343,000)
Unvested at the end of the year (in shares)	4,561,000	2,918,000	3,171,000
Weighted Average Grant Date Fair Value Per Share
Granted (in dollars per share)	$ 3.75	$ 4.16	$ 2.74
Performance Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)	280,000	419,000	0
Granted (in shares)	937,000	280,000	419,000
Vested (in shares)	0	0
Cancelled/Forfeited (in shares)	(642,000)	(419,000)
Unvested at the end of the year (in shares)	575,000	280,000	419,000
Market Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)	0	171,000	641,000
Granted (in shares)	0	0	0
Vested (in shares)	0	0	0
Cancelled/Forfeited (in shares)	0	(171,000)	(470,000)
Unvested at the end of the year (in shares)		0	171,000
Restricted Stock Units, Performance Stock Units and Market Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)	3,198,000	3,761,000	3,725,000
Granted (in shares)	4,173,000	2,018,000	2,428,000
Vested (in shares)	(1,341,000)	(1,452,000)	(1,579,000)
Cancelled/Forfeited (in shares)	(894,000)	(1,129,000)	(813,000)
Unvested at the end of the year (in shares)	5,136,000	3,198,000	3,761,000
Weighted Average Grant Date Fair Value Per Share
Unvested at the beginning of the year (in dollars per share)	$ 3.73	$ 3.26	$ 4.34
Granted (in dollars per share)	3.75	4.16	2.74
Vested (in dollars per share)	3.75	3.52	4.62
Cancelled/Forfeited (in dollars per share)	3.87	3.20	3.96
Unvested at the end of the year (in dollars per share)	$ 3.74	$ 3.73	$ 3.26

Stock Incentive Plan and Empl_9

Stock Incentive Plan and Employee Stock Purchase Plan - ESPP (Details) - ESPP	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Weighted average assumptions used for determining fair value of options
Risk-free interest rate, Minimum (as a percent)	0.10%	0.04%	0.17%
Risk-free interest rate, Maximum (as a percent)	2.16%	0.10%	1.60%
Expected volatility, Minimum (as a percent)	35.49%	36.10%	45.46%
Expected volatility, Maximum (as a percent)	54.33%	65.58%	75.21%
Minimum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	6 months	6 months	6 months
Maximum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	1 year	1 year	1 year

Joint Venture - Additional Info

Joint Venture - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jan. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Gain on contribution to joint venture	$ 0	$ 0	$ 12,964,000
Increase to accumulated deficit	(492,522,000)	(488,024,000)
Currency translation adjustment	(120,000)	243,000
Proportional share of underlying equity in net assets, difference amount	1,700,000
Goodwill	57,840,000	57,960,000	57,717,000
Impairment of goodwill	$ 0	$ 0	$ 0
Accuray Asia
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership interest in joint venture	49%			49%
Percentage of ownership interest in joint venture		49%
Increase to accumulated deficit	$ 1,000,000
Deferred of intra-entity profit margin	4,700,000	$ 2,100,000
Previously deferred intra-entity margin from system sales	1,400,000	1,800,000
Deferral of intra entity margin from system sales	4,700,000	$ 2,100,000
Equity method investment	13,900,000
Proportional share of underlying equity in net assets	14,600,000
Currency translation adjustment	1,000,000
Elimination of equity method investment intra-entity profit on sales	5,400,000
Goodwill	4,700,000
Impairment of goodwill	$ 0

Joint Venture - Summary of Fina

Joint Venture - Summary of Financial Information of Joint Ventures (Operations Data) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020
Schedule Of Equity Method Investments [Line Items]
Total net revenue	$ 429,909		$ 396,289		$ 382,928
Gross Profit	159,955		159,507		149,721
Net income	$ (5,347)		$ (6,311)		$ 3,827
CNNC Accuray (Tianjin) Medical Technology Co. Ltd.
Schedule Of Equity Method Investments [Line Items]
Total net revenue		$ 55,190		$ 33,054
Gross Profit		15,915		10,578
Net income		422		1,785
Net income attributable to the Company		$ 241		$ 872

Joint Venture - Summary of Fi_2

Joint Venture - Summary of Financial Information of Joint Ventures (Balance Sheet Data) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2019
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 350,890		$ 352,773
Total assets	472,849		480,098
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities	208,858		192,359
Stockholder's equity	53,189		68,840		$ 63,635	$ 49,871
Total liabilities and stockholders’ equity	$ 472,849		$ 480,098
CNNC Accuray (Tianjin) Medical Technology Co. Ltd.
Schedule Of Equity Method Investments [Line Items]
Current assets		$ 71,730		$ 24,703
Non current assets		21,754		23,089
Total assets		93,484		47,792
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities		61,877		16,854
Non current liabilities		1,055		1,467
Stockholder's equity		30,552		29,471
Total liabilities and stockholders’ equity		$ 93,484		$ 47,792

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income (Loss) Before Provision for Income Taxes on the Accompanying Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Components of income (loss) before provision for income taxes
Domestic	$ (14,092)	$ (8,448)	$ (1,811)
Foreign	12,090	3,889	7,501
Income (loss) before provision for income taxes	$ (2,002)	$ (4,559)	$ 5,690

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Current:
State	$ 25	$ 17	$ 15
Foreign	1,535	1,849	1,495
Total current	1,560	1,866	1,510
Deferred:
Foreign	1,785	(114)	353
Total deferred	1,785	(114)	353
Total provision for income taxes	$ 3,345	$ 1,752	$ 1,863

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to the Provision for Income Taxes Included in the Accompanying Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
U.S. federal taxes (benefit):
At federal statutory rate	$ (420)	$ (958)	$ 1,195
State tax, net of federal benefit	25	17	15
Share-based compensation expense	592	879	810
Debt extinguishment	0	898
Other non-deductible permanent items	252	155	418
R&D credits	(415)	(1,278)	(635)
Foreign taxes	(948)	918	273
Other	(97)	(57)	(69)
Deferred Tax on foreign earnings	1,730	0	0
Global Intangible Low-Taxed Income	2,124	243	1,185
Change in valuation allowance	502	935	(1,329)
Total provision for income taxes	$ 3,345	$ 1,752	$ 1,863

Income Taxes - Schedule of Sign

Income Taxes - Schedule of Significant Components of Net Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Deferred tax assets:
Federal and state net operating losses	$ 75,450	$ 75,033
Accrued expenses and reserves	7,359	6,597
Lease liability	3,037	4,258
Deferred revenue	5,505	5,093
R&D Credits	25,146	24,340
Share-based compensation expense	1,406	1,096
Capitalized research and development	1,440	2,088
Unicap	489	1,827
Fixed assets/intangibles	956	1,055
Section 163(j) interest	2,350	1,817
Other	228	1,082
Total deferred tax assets	123,366	124,286
Deferred tax liabilities:
Contract acquisition costs	(1,521)	(1,174)
Right of use assets	(2,517)	(3,533)
Debt	0	(5,612)
Deferred tax on foreign earnings	(1,730)	0
Total deferred tax liabilities	(5,768)	(10,319)
Valuation allowance	(119,115)	(113,476)
Net deferred tax assets (liabilities)	$ (1,517)
Net deferred tax assets (liabilities)		$ 491

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Income Taxes [Line Items]
Valuation allowance percentage established for domestic and foreign net assets	100%
Undistributed earnings of foreign subsidiaries	$ 18,100
Tax expected to be paid on the remittance of unrepatriated distributable reserves	$ 1,700
Subsequent period within which no material changes in unrecognized tax benefits are expected	12 months
Gross unrecognized tax benefits	$ 19,810	$ 18,765	$ 16,996	$ 16,280
Uncertain tax benefits that, if realized, would affect the effective tax rate	19,600
Accrued interest and penalties related to uncertain tax positions	$ 60	$ 50
Minimum
Income Taxes [Line Items]
Statutes of limitations with respect to jurisdictions (in years)	3 years
Maximum
Income Taxes [Line Items]
Statutes of limitations with respect to jurisdictions (in years)	10 years
Research and development
Income Taxes [Line Items]
Tax credits	$ 22,100
Federal
Income Taxes [Line Items]
Net operating loss carryforwards	324,000
Tax credits	25,500
State
Income Taxes [Line Items]
Net operating loss carryforwards	$ 131,100

Income Taxes - Schedule of Aggr

Income Taxes - Schedule of Aggregate Changes in the Balance of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Aggregate changes in the balance of gross unrecognized tax benefits
Balance at beginning of year	$ 18,765	$ 16,996	$ 16,280
Tax positions related to current year: Additions	1,222	1,433	954
Tax positions related to prior years: Additions	61	786	286
Tax positions related to prior years: Reductions	(238)	(450)	(524)
Balance at end of year	$ 19,810	$ 18,765	$ 16,996

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Retirement Benefits [Abstract]
Employer's contribution to the 401(k) Plan	$ 2.3	$ 1.1	$ 2

Defined Benefit Pension Oblig_3

Defined Benefit Pension Obligation - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Defined Benefit Pension Obligation
Actuarial gain	$ 4,300
Defined benefit pension plan
Defined Benefit Pension Obligation
Actuarial gain	3,460	$ 807
Employer contributions	1,225	$ 1,117	$ 1,300
Expected total contributions to defined benefit pension plan for fiscal year 2023	$ 1,300
Defined benefit pension plan | BVG
Plan Assets
Guaranteed interest rate for mandatory retirement savings (as a percent)	1%	1%
Long-term other liabilities
Defined Benefit Pension Obligation
Unfunded liability	$ 100

Defined Benefit Pension Oblig_4

Defined Benefit Pension Obligation - Obligations and Funded Status (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Change in benefit obligation:
Actuarial (gain)/loss	$ (4,300)
Amounts recognized within the consolidated balance sheets:
Assets	472,849	$ 480,098
Defined benefit pension plan
Change in benefit obligation:
Benefit obligation—beginning of fiscal year	18,705	18,426
Service cost	1,513	1,766	$ 2,003
Interest cost	75	38	62
Plan participants’ contributions	2,554	1,676
Plan amendment	(699)	25
Actuarial (gain)/loss	(3,460)	(807)
Foreign currency changes	(577)	281
Benefit and expense payments	(658)	(2,700)
Benefit obligation—end of fiscal year	17,453	18,705	18,426
Change in plan assets:
Plan assets—beginning of fiscal year	14,419	13,958
Employer contributions	1,225	1,117	1,300
Actual return on plan assets	374	199
Plan participants’ contributions	2,554	1,676
Foreign currency changes	(564)	169
Benefit and expense payments	(658)	(2,700)
Plan assets—end of fiscal year	17,350	14,419	$ 13,958
Funded status	(103)	(4,286)
Amounts recognized within the consolidated balance sheets:
Long-term other liabilities	(103)	(4,286)
Net amount recognized	$ (103)	$ (4,286)

Defined Benefit Pension Oblig_5

Defined Benefit Pension Obligation - Amounts Recognized (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Amounts recognized within the consolidated balance sheets:
Assets	$ 472,849	$ 480,098
Defined benefit pension plan
Amounts recognized within the consolidated balance sheets:
Long-term other liabilities	(103)	(4,286)
Net amount recognized	(103)	(4,286)
Amounts recognized in accumulated other comprehensive loss (before tax)
Net actuarial loss (gain)	3,723	(1,236)
Prior service cost	224	872
Accumulated other comprehensive income (loss)	3,947	(364)
Accumulated benefit obligations in excess of fair value of plan assets:
Projected benefit obligation	17,453	18,705
Accumulated benefit obligation	15,546	16,891
Fair value of plan assets	$ 17,350	$ 14,419

Defined Benefit Pension Oblig_6

Defined Benefit Pension Obligation - Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Loss (Details) - Defined benefit pension plan - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2023
Net Periodic Benefit Costs:
Service cost	$ 1,513	$ 1,766	$ 2,003
Interest cost	75	38	62
Expected returns on assets	(144)	(142)	(151)
Amortization of prior service cost	54	54	(2)
Settlement charges			178
Net periodic benefit costs	1,498	1,716	2,090
Other Amounts Recognized in Other Comprehensive Loss:
Net (gain) loss arising during the year	(3,584)	(850)	(593)
Prior service cost	(53)	(54)	2
Amortization of prior service cost	(678)	24	1,005
Effect of settlement	4	8	(178)
Total recognized in other comprehensive (gain) loss	(4,311)	(872)	236
Total recognized in net periodic benefit costs and other comprehensive loss	$ (2,813)	$ 844	$ 2,326
Scenario Forecast
Amounts in accumulated other comprehensive loss that are expected to be recognized as components of net periodic benefit cost during fiscal year 2021
Net gain				$ 172
Prior service credit				24
Accumulated other comprehensive loss				$ 196

Defined Benefit Pension Oblig_7

Defined Benefit Pension Obligation - Assumptions (Details) - Defined benefit pension plan	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Net Periodic Benefit Costs:
Discount rate (as a percent)	1.90%	0.40%	0.25%
Rate of compensation increase (as a percent)	1.75%	1.50%	1.50%
Expected long-term return on assets (as a percent)	1%	1%	1%
Benefit Obligation:
Discount rate (as a percent)	1.90%	0.40%
Rate of compensation increase (as a percent)	1.75%	1.50%

Defined Benefit Pension Oblig_8

Defined Benefit Pension Obligation - Estimated Contributions and Future Benefit Payments (Details) - Defined benefit pension plan $ in Thousands	Jun. 30, 2022 USD ($)
Future Benefit Payments
2023	$ 1,001
2024	1,015
2025	1,212
2026	1,054
2027	1,218
Thereafter	8,605
Total	$ 14,105

Segment Disclosure - Additional

Segment Disclosure - Additional Information (Details)	12 Months Ended
	Jun. 30, 2022 Segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Segment Disclosure - Summary of

Segment Disclosure - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Segment Information
Total net revenue	$ 429,909	$ 396,289	$ 382,928
Americas
Segment Information
Total net revenue	126,005	105,878	128,562
Europe, Middle East, India and Africa
Segment Information
Total net revenue	134,640	121,568	119,989
Asia Pacific, excluding Japan and China
Segment Information
Total net revenue	28,953	26,425	31,297
Japan
Segment Information
Total net revenue	53,376	62,636	72,688
China
Segment Information
Total net revenue	$ 86,935	$ 79,782	$ 30,392

Segment Disclosure - Schedule o

Segment Disclosure - Schedule of Geographic Areas in Which the Company has Long-Lived Tangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Segment Information
Long lived tangible assets	$ 12,685	$ 12,332
Americas
Segment Information
Long lived tangible assets	11,251	10,588
Europe, Middle East, India and Africa
Segment Information
Long lived tangible assets	228	265
Asia Pacific, excluding Japan and China
Segment Information
Long lived tangible assets	272	170
Japan
Segment Information
Long lived tangible assets	265	701
China
Segment Information
Long lived tangible assets	$ 669	$ 608

Restructuring Charges (Details)

Restructuring Charges (Details) - USD ($)		12 Months Ended
	May 27, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Restructuring and Severance Charges
Accrued restructuring charges				$ 600,000
Employee severance
Restructuring and Severance Charges
Workforce affected by cost saving initiative (as a percent)	3%
Restructuring charges		$ 0	$ 0	500,000
Employee severance | Cost of Goods Sold and Operating Expense
Restructuring and Severance Charges
Restructuring charges				$ 1,100,000

Quarterly Financial Data (unaud

Quarterly Financial Data (unaudited) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Quarterly Financial Data [Abstract]
Net revenue	$ 429,909	$ 396,289	$ 382,928
Gross Profit	159,955	159,507	149,721
Net income	$ (5,347)	$ (6,311)	$ 3,827
Net income (loss) per share - basic	$ (0.06)	$ (0.07)	$ 0.04
Net income (loss) per share - diluted	$ (0.06)	$ (0.07)	$ 0.04
Weighted average common shares used in computing net income (loss) per share:
Basic	92,095	92,031	89,874
Diluted	92,095	92,031	90,623